

CURRICULUM VITAE**STEVEN EMANUEL KAHN, M.B., Ch.B.**Personal Data:

Place and Date of Birth: Durban, South Africa; July 28, 1955
Marital Status: Married (Stephanie Berk); two children
Citizenship: U.S.A.

Education:

Glenwood High School, Durban, South Africa, 1968-1972
University of Cape Town, South Africa, M.B., Ch.B., 1973-1978

National Service:

Compulsory National Service, South African Medical Services, 1980-1981

Postgraduate Training:

1979: Intern, Departments of Obstetrics and Gynecology and Medicine, Somerset Hospital, Cape Town, South Africa

1980: Resident, Department of Obstetrics and Gynecology, 2 Military Hospital, Wynberg, South Africa

1981: Resident and Coordinator, Department of Obstetrics and Gynecology, 2 Military Hospital, Wynberg, South Africa

1982: Resident, Division of Endocrinology, Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa

1983: Research Fellow, Diabetes and Endocrine Research Group, Department of Medicine, University of Cape Town, Cape Town, South Africa

1983-1986: Resident, Department of Medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania

1986-1988: Senior Research Fellow, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine and Veterans Affairs Medical Center, Seattle, Washington

Positions Held:

- 1988-1991: Associate Investigator and Staff Physician, Division of Endocrinology and Metabolism, Department of Medicine, Veterans Affairs Medical Center, Seattle, Washington
- 1988-1992: Acting Instructor, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, Washington
- 1991-1995: Research Associate and Staff Physician, Division of Endocrinology and Metabolism, Department of Medicine, Veterans Affairs Medical Center, Seattle, Washington
- 1992-1995: Assistant Professor, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, Washington
- 1995-2001: Associate Professor, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, Washington
- 1995-2001: Associate Program Director, General Clinical Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, Washington
- 1995-2011: Associate Director, Diabetes Endocrinology Research Center, University of Washington School of Medicine, Seattle, Washington
- 2001-present: Professor, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, Washington
- 2001-2009: Associate Chief of Staff for Research and Development and Staff Physician, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
- 2011-present: Director, Diabetes Research Center, University of Washington School of Medicine, Seattle, Washington

Honors:

- 1973-1975: Amelia Schenkman Scholarship, University of Cape Town
- 1984: Herman Ostrum Memorial Award, Albert Einstein Medical Center, Philadelphia
- 1984: Resident Achievement Award, Albert Einstein Medical Center, Philadelphia
- 1988: Associate Investigator of the Department of Veterans Affairs
- 1988: Juvenile Diabetes Foundation Career Development Award
- 1989: Dana Foundation Feasibility Award
- 1991: Research Associate of the Department of Veterans Affairs

- 1991: NIH Clinical Investigator Award
1992-1994: Diabetes Research Council New Investigator Award
1999: Pfizer Visiting Professor in Diabetes to Case Western Reserve University
2001: Novartis Young Investigator in Diabetes Award
2003: Pfizer Visiting Professor in Diabetes to University of Texas, Houston and Baylor College of Medicine, Houston
2004: Bernard Pimstone Memorial Lecture, Society for Endocrinology, Metabolism and Diabetes of South Africa
2004: American Diabetes Association Distinguished Clinical Scientist Award
2005: Robert H. Williams - Rachmiel Levine Award
2006: McGill Lectureship on Metabolism, McGill University, Montreal
2007: Banting and Best Lecture, Canadian Diabetes Association
2009: The Endocrine Society and Pfizer International Award for Excellence in Published Clinical Research
2010: Lydia J. Roberts Memorial Lecture, University of Chicago
2010: Alexander Marble Lectureship on Diabetes, Joslin Diabetes Center and Beth Israel Deaconess Medical Center, Boston
2010: Kroc Lecture, Uppsala University, Uppsala, Sweden
2013: J. Denis McGarry Lecture, Montreal Diabetes Research Center, Montreal
2013: David Rabin Lecture, Vanderbilt University, Nashville
2013: McGill Novo-Nordisk Diabetes Lecture, McGill University, Montreal
2013: The Endocrine Society Clinical Investigator Award
2013: Department of Veterans Affairs John B. Barnwell Award
2013: Glassman Memorial Lecture, The Hebrew University of Jerusalem, Israel
2014: Stanley Mirski Lecture, Icahn School of Medicine at Mount Sinai, New York
2014: European Association for the Study of Diabetes Albert Renold Award
2014: Stefan S. Fajans Lecture in Diabetes, University of Michigan, Ann Arbor
2014: Leonard L. Wright and Marjorie C. Wright Chair, University of Washington
2015: Kroc Lecture, University of Chicago
2015: D. Walter Cohen Lectureship in Diabetes, Drexel University College of Medicine, Philadelphia
2016: Catherine Tuck Lecture, Columbia University, New York
2016: American Diabetes Association Outstanding Achievement in Clinical Diabetes Research Award

Board Certification:

- 1978: Educational Commission for Foreign Medical Graduates (ECFMG)
1983: FLEX
1986: American Board of Internal Medicine
1989: American Board of Internal Medicine (Endocrinology and Metabolism)

Current Licensure:

- 1979: South African Medical and Dental Council - Medical Practitioner
1984: Pennsylvania State Board of Medicine - Medical Practitioner
1986: Washington State Board of Medicine - Medical Practitioner

Professional Memberships:

American Association of Physicians
 American College of Physicians
 American Diabetes Association
 American Federation for Medical Research
 American Society for Clinical Investigation
 European Association for the Study of Diabetes
 The Endocrine Society
 Western Association of Physicians
 Western Society for Clinical Investigation

Editorial Responsibilities:

1995-1998: Editorial Board, The Journal of Clinical Endocrinology and Metabolism
 1997-1999: Editorial Board, Diabetes Care
 2001-2004: Editorial Board, The Journal of Clinical Endocrinology and Metabolism
 2005-2007: Associate Editor, The Journal of Clinical Endocrinology and Metabolism
 2005-2008: Editorial Board, Diabetes
 2007-2015: Editorial Board, Clinical and Translational Science
 2008-2009: Deputy Editor, The Journal of Clinical Endocrinology and Metabolism
 2010-present: Editorial Board, Annals of the New York Academy of Sciences
 2012-2014: Associate Editor, Journal of Diabetes and its Complications
 2015-present: Associate Editor, Diabetologia
 2016-present: Associate Editor, Diabetes Care

Special National and International Responsibilities:

1994: Chair, Program Committee for Metabolism, Western Regional Meetings of American Federation for Medical Research, American Society for Clinical Investigation
 1994-1996: Councilor, Western Section, American Federation for Medical Research
 1994-1997: Member and Vice-Chair, Research Grant Review Panel, American Diabetes Association
 1996: Chair, Program Committee for Metabolism, Western Regional Meetings of American Federation for Medical Research, American Society for Clinical Investigation
 1996-1998: Chair-Elect and Chair, Western Section, American Federation for Medical Research and National Councilor, American Federation for Medical Research
 1998: Chair, Program Committee for Metabolism, Western Regional Meetings of American Federation for Medical Research, American Society for Clinical Investigation
 2001-2003: President-Elect and President, Western Society for Clinical Investigation
 2002: Chair, Program Committee for Metabolism, Western Regional Meetings of American Federation for Medical Research, American Society for Clinical Investigation
 2001-2002: Member, Scientific and Medical Meetings Oversight Committee, American Diabetes Association

- 2002-2004: Chair, Scientific and Medical Meetings Oversight Committee, American Diabetes Association
- 2002-2005: Member, Board of Directors, American Diabetes Association
- 2004-2006: Member, Professional Practice Committee, American Diabetes Association
- 2004-2006: Member, Task Force on Effective Governance, American Diabetes Association
- 2005: Course Director, 52nd American Diabetes Association Postgraduate Course
- 2005: Member, Scientific Program Committee, 41st Annual Meeting of the European Association for the Study of Diabetes
- 2006: Course Director, 53rd American Diabetes Association Postgraduate Course
- 2008-2012: Member, Scientific Statements Task Force, The Endocrine Society
- 2009: Member, Chief Scientific Officer Search Committee, American Diabetes Association
- 2008-2009: Member, Scientific Program Committee, 20th World Diabetes Congress of the International Diabetes Federation
- 2010-2011: Co-chair, Obesity and Diabetes Working Group, The Endocrine Society, American Diabetes Association and European Association for the Study of Diabetes
- 2010-2011: Chair, Clinical and Basic Science Stream, Scientific Program Committee, 21st World Diabetes Congress of the International Diabetes Federation
- 2010-2013: Member, Publications Core Committee, The Endocrine Society
- 2011: Member, Chief Scientific Officer Search Committee, American Diabetes Association
- 2011-present: Vice-Chair, Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Research Group (NIDDK sponsored multicenter clinical trial)
- 2011-present: Chair, Restoring Insulin Secretion (RISE) Study Group (NIDDK sponsored multicenter clinical trial)
- 2012-2013: Member, Scientific Program Committee, 22nd World Diabetes Congress of the International Diabetes Federation
- 2012-present: Member, American Diabetes Association Research Policy Committee
- 2014-2015: Chair, Clinical and Basic Science Stream, Scientific Program Committee, 23rd World Diabetes Congress of the International Diabetes Federation
- 2013-present: Member, American Diabetes Association Mentor Advisory Group

Special Local Responsibilities:

- 1990-2001: General Clinical Research Center Scientific Advisory Committee, University of Washington
- 1992-1993: Scientific Review Committee, VA Puget Sound Health Care System
- 1993-1998: Board of Directors and Executive, American Diabetes Association, Washington Affiliate
- 1999-2009: VA Research and Development Committee, VA Puget Sound Health Care System
- 2001-2009: Dean's Committee, University of Washington and VA Puget Sound Health Care System
- 2001-2009: Member, Board of Directors, Seattle Institute for Biomedical and Clinical Research

BIBLIOGRAPHY

Steven Emanuel Kahn, M.B., Ch.B.

Peer Reviewed Publications of Original Work

1. Kahn SE, Miller JL: Rapid resolution of visual field defects and reduction in macroprolactinoma size with bromocriptine therapy: a case report. *S Afr Med J* 62:696-699; 1982.
2. Kahn SE, Klaff LJ: The importance of metabolic control in diabetes mellitus. *S Afr J Cont Med Ed* 1:iii 15-23; 1983.
3. Kahn SE, Maxwell JU, Barron JL: Salivary cortisol assessment in the evaluation of hypothalamic-pituitary-adrenal function. *S Afr Med J* 65:843-846; 1984.
4. Ismail F, Miller JL, Kahn SE, Willcox P: Hypothalamic-pituitary sarcoidosis: a case report and review of the literature. *S Afr Med J* 67:139-142; 1985.
5. Kahn SE, Goldstein J, Cope C: Low-dose streptokinase therapy for Swan-Ganz catheter-induced thrombosis. *Am Heart J* 110:891-893; 1985.
6. Kahn SE, Kotler MN, Goldman AP, Ablaza S: Superior vena cava obstruction secondary to acute dissecting aneurysm of the aorta. *Am Heart J* 111:606-608; 1986.
7. Kochar G, Kahn SE, Kotler MN: Bretylium tosylate and ventricular fibrillation in hypothermia. *Ann Int Med* 105:624; 1986.
8. Feitelberg SP, Kahn SE, Kotler MN, Cope C, Nakhjavan FK, Lippmann M: Transfemoral embolectomy for massive pulmonary embolus and associated myocardial infarction. *Am Heart J* 113:819-820; 1987.
9. McCulloch DK, Raghu PK, Johnston C, Klaff LJ, Kahn SE, Beard JC, Ward WK, Benson EA, Koerker DJ, Bergman RN, Palmer JP: Defects in β -cell function and insulin sensitivity in normoglycemic streptozocin-treated baboons: a model of preclinical insulin-dependent diabetes. *J Clin Endocrinol Metab* 67:785-792; 1988.
10. Schumer M, Miller-Crain G, Pfeifer MA, The Statil Study Group: Diabetic autonomic neuropathy - part II: coefficient of variation of RR-variation and Valsalva maneuver tests. *Am J Med* 85 (Suppl 5A):144-146; 1988.
11. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ Jr, Porte D Jr: Increased β -cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. *Diabetes* 38:562-568; 1989.
12. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β -cell dysfunction? *Diabetes* 38:1333-1336; 1989.

13. McCulloch DK, Klaff LJ, Kahn SE, Schoenfeld SL, Greenbaum CJ, Mauseth R, Benson EA, Nepom GT, Shewey L, Palmer JP: Nonprogression of subclinical β -cell dysfunction among first-degree relatives of IDDM patients: 5-yr follow-up of the Seattle family study. *Diabetes* 39:549-556; 1990.
14. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensink JW, Taborsky GJ Jr, Porte D Jr: Evidence of cosecretion of islet amyloid polypeptide and insulin by β -cells. *Diabetes* 39:634-638; 1990.
15. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowalyk S, Bennett PH, Porte D Jr: Disproportionately elevated proinsulin in Pima Indians with non-insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 70:1247-1253; 1990.
16. Kahn SE, Larson VG, Beard JC, Cain KC, Fellingham GW, Schwartz RS, Veith RC, Stratton JR, Cerqueira MD, Abrass IB: Effect of exercise on insulin action, glucose tolerance and insulin secretion in aging. *Am J Physiol* 258:E937-E943; 1990.
17. Schwartz MW, Figlewicz DF, Kahn SE, Baskin DG, Greenwood MRC, Porte D Jr: Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. *Peptides* 11:467-472; 1990.
18. Kahn SE, Klaff LJ, Schwartz MW, Beard JC, Bergman RN, Taborsky GJ Jr, Porte D Jr: Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. *J Clin Endocrinol Metab* 71:994-1002; 1990.
19. Schwartz MW, Sipols A, Kahn SE, Lattemann DF, Taborsky GJ Jr, Bergman RN, Woods SC, Porte D Jr: Kinetics and specificity of insulin uptake from plasma into cerebrospinal fluid. *Am J Physiol* 259:E378-E383; 1990.
20. Schwartz RS, Shuman WP, Bradbury VL, Cain KC, Fellingham GW, Beard JC, Kahn SE, Stratton JR, Cerqueira MD, Abrass IB: Body fat distribution in healthy young and older men. *J Gerontol* 45:M181-M185; 1990.
21. McCulloch DK, Kahn SE, Schwartz MW, Koerker DJ, Palmer JP: Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. *J Clin Invest* 87:1395-1401; 1991.
22. Schwartz RS, Shuman WP, Larson V, Cain KC, Fellingham GW, Beard JC, Kahn SE, Stratton JR, Cerqueira MD, Abrass IB: The effect of intensive endurance exercise training on body fat distribution in young and older men. *Metabolism* 40:545-551; 1991.
23. Schwartz MW, Marks JL, Sipols AJ, Baskin DG, Woods SC, Kahn SE, Porte D Jr: Central insulin administration reduces neuropeptide Y mRNA expression in the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker rats. *Endocrinology* 128:2645-2647; 1991.
24. Stratton JR, Chandler WL, Schwartz RS, Cerqueira MD, Levy WC, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB: Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. *Circulation* 83:1692-1697; 1991.

25. McCulloch DK, Koerker DJ, Kahn SE, Bonner-Weir S, Palmer JP: Correlations of in vivo β -cell function tests with β -cell mass and pancreatic insulin content in streptozocin-administered baboons. *Diabetes* 40:673-679; 1991.
26. Schwartz MW, Bergman RN, Kahn SE, Taborsky GJ Jr, Fisher LD, Sipols AJ, Woods SC, Steil GM, Porte D Jr: Evidence for entry of plasma insulin into cerebrospinal fluid through an intermediate compartment in dogs. Quantitative aspects and implications for transport. *J Clin Invest* 88:1272-1281; 1991.
27. Kahn SE, Fujimoto WY, D'Alessio DA, Ensinnck JW, Porte D Jr: Glucose stimulates and potentiates islet amyloid polypeptide secretion by the B-cell. *Horm Metab Res* 23:577-580; 1991.
28. Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte D Jr: Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. *J Clin Endocrinol Metab* 74:192-197; 1992.
29. Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr: Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. *Am J Physiol* 262:E518-E523; 1992.
30. Kahn SE, Larson VG, Schwartz RS, Beard JC, Cain KC, Fellingham GW, Stratton JR, Cerqueira MD, Abrass IB: Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. *J Clin Endocrinol Metab* 74:1336-1342; 1992.
31. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, Figlewicz DP, Porte D Jr: Inhibition of hypothalamic neuropeptide Y gene expression by insulin. *Endocrinology* 130:3608-3616; 1992.
32. Schwartz RS, Cain KC, Shuman WP, Larson V, Stratton JR, Beard JC, Kahn SE, Cerqueira MD, Abrass IB: Effect of intensive endurance training on lipoprotein profiles in young and older men. *Metabolism* 41:649-654; 1992.
33. Chandler WL, Veith RC, Fellingham GW, Levy WC, Schwartz RS, Cerqueira MD, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB, Stratton JR: Fibrinolytic response during exercise and epinephrine infusion in the same subjects. *J Am Coll Cardiol* 19:1412-1420; 1992.
34. Stratton JR, Cerqueira MD, Schwartz RS, Levy WC, Veith RC, Kahn SE, Abrass IB: Differences in cardiovascular responses to isoproterenol in relation to age and exercise training in healthy men. *Circulation* 86:504-512; 1992.
35. Steil GM, Volund A, Kahn SE, Bergman RN: Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. *Diabetes* 42:250-256; 1993.
36. Abbate SL, Fujimoto WY, Brunzell JD, Kahn SE: Effect of heparin on insulin-glucose interactions measured by the minimal model technique: implications for reproducibility using this method. *Metabolism* 42:353-357; 1993.

37. Neifing JL, Greenbaum CJ, Kahn SE, McCulloch DK, Bärmeier H, Lernmark Å, Palmer JP: Prospective evaluation of beta cell function in insulin autoantibody positive relatives of insulin-dependent diabetic patients. *Metabolism* 42:482-486; 1993.
38. Kahn SE, Verchere CB, D'Alessio DA, Cook DL, Fujimoto WY: Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. *Diabetologia* 36:570-573; 1993.
39. Kahn SE, Horber FF, Prigeon RL, Haymond MW, Porte D Jr: Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans. *Diabetes* 42:1082-1085; 1993.
40. Baura GD, Foster DM, Porte D Jr, Kahn SE, Bergman RN, Cobelli C, Schwartz MW: Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: a mechanism for regulated insulin delivery to the brain. *J Clin Invest* 92:1824-1830; 1993.
41. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. *Diabetes* 42:1663-1672; 1993.
42. Prigeon RL, Kahn SE, Porte D Jr: Reliability of error estimates from the minimal model: implications for measurements in physiological studies. *Am J Physiol* 266:E279-E286; 1994.
43. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: The contribution of insulin dependent and insulin independent glucose uptake to intravenous glucose tolerance in healthy human subjects. *Diabetes* 43:587-592; 1994.
44. Haymond MW, Horber FF, DeFeo P, Kahn SE, Mauras N: Effect of human growth hormone and insulin-like growth factor 1 on whole-body leucine and estimates of protein metabolism. *Horm Res* 40:92-94; 1993.
45. D'Alessio DA, Kahn SE, Leusner C, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. *J Clin Invest* 93:2263-2266; 1994.
46. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD: The visceral adiposity syndrome in Japanese-American men. *Obes Res* 2:364-371; 1994.
47. Verchere CB, D'Alessio DA, Palmiter RD, Kahn SE: Transgenic mice overproducing human islet amyloid polypeptide have increased insulin storage and secretion. *Diabetologia* 37:725-728; 1994.
48. Stone LM, Kahn SE, Deeb SS, Fujimoto WY, Porte D Jr: Glucokinase gene variations in Japanese-Americans with a family history of NIDDM. *Diabetes Care* 17:1480-1483; 1994.
49. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW: Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. *Diabetes* 43:1457-1461; 1994.

50. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY: Proinsulin as a marker for the development of NIDDM in Japanese-American men. *Diabetes* 44:173-179; 1995.
51. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY: Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese American men: impact of obesity. *J Clin Endocrinol Metab* 80:1399-1406; 1995.
52. Schwartz MW, Boyko EJ, Kahn SE, Ravussin E, Bogardus C: Reduced insulin secretion: an independent predictor of weight gain. *J Clin Endocrinol Metab* 80:1571-1576; 1995.
53. Prigeon RL, Kahn SE, Porte D Jr: Changes in insulin sensitivity, glucose effectiveness, and B-cell function in regularly exercising subjects. *Metabolism* 44:1259-1263; 1995.
54. Baura GD, Foster DM, Kaiyala K, Porte D Jr, Kahn SE, Schwartz MW: Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. *Diabetes* 45:86-90; 1996.
55. Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D Jr, Robertson RP: Hemipancreatectomy causes hyperproinsulinemia in non-diabetic humans. *J Clin Invest* 97:455-460; 1996.
56. Prigeon RL, Røder ME, Porte D Jr, Kahn SE: The effect of insulin dose on the measurement of insulin sensitivity by the minimal model technique: Evidence for saturable insulin transport in humans. *J Clin Invest* 97:501-507; 1996.
57. Stone LM, Kahn SE, Fujimoto WY, Deeb SS, Porte D Jr: A variation at position -30 of the β -cell glucokinase gene promoter is associated with reduced β -cell function in middle-aged Japanese-American men. *Diabetes* 45:422-428; 1996.
58. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. *Proc Natl Acad Sci USA* 93:3492-3496; 1996.
59. Best JD, Kahn SE, Ader M, Watanabe RM, Ni T-C, Bergman RN: Role of glucose effectiveness in the determination of glucose tolerance. *Diabetes Care* 19:1018-1030; 1996.
60. Prigeon RL, Jacobson RK, Porte D Jr, Kahn SE: Effect of sulfonylurea withdrawal on proinsulin levels, B-cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 81:3295-3298; 1996.
61. Kahn SE, Leonetti DL, Prigeon RL, Bergstrom RW, Fujimoto WY: Proinsulin levels predict the development of non-insulin dependent diabetes mellitus (NIDDM) in Japanese-American men. *Diabetic Med* 13:S63-S66; 1996.
62. Greenbaum CJ, Kahn SE, Palmer JP: Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. *Diabetes* 45:1631-1634; 1996.
63. Verchere CB, Paoletta M, Neerman-Arbez M, Rose K, Gingerich RL, Kahn SE, Halban PA: Des-(27-31)C-peptide: a novel secretory product of the rat pancreatic beta cell produced by truncation of proinsulin connecting peptide in secretory granules. *J Biol Chem* 271:27475-27481; 1996.

64. Verchere CB, D'Alessio DA, Wang S, Andrikopoulos S, Kahn SE: Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation. *Horm Metab Res* 29:311-316; 1997.
65. Schwartz MW, Prigeon RL, Kahn SE, Nicolson M, Moore J, Morawiecki A, Boyko EJ, Porte D Jr: Evidence that plasma leptin and insulin levels are associated with body adiposity via different mechanisms. *Diabetes Care* 20:1476-1481; 1997.
66. Verchere CB, D'Alessio DA, Andrikopoulos S, Kahn SE: A transgenic mouse model of pancreatic islet amyloid formation. *Comp Path Bull* 30:4-5; 1997.
67. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. *Diabetes* 46:1725-1732; 1997.
68. Ensink JW, Vogel RE, Laschansky EC, Koerker D, Prigeon RL, Kahn SE, D'Alessio DA: Endogenous somatostatin-28 modulates of postprandial insulin secretion: immunoneutralization studies in baboons. *J Clin Invest* 100:2295-2302; 1997.
69. Røder ME, Porte D Jr, Kahn SE: Disproportionately elevated proinsulin levels reflect the degree of impaired B-cell secretory capacity in patients with non-insulin dependent diabetes mellitus. *J Clin Endocrinol Metab* 83:604-608; 1998.
70. Prigeon RL, Røder ME, Kahn SE, Porte D Jr: Effects of troglitazone on proinsulin release and other factors related to glucose tolerance in NIDDM. *J Clin Endocrinol Metab* 83:819-823; 1998.
71. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, Boyko EJ, Schwartz RS, Newell-Morris L, Fujimoto WY: Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes mellitus in Japanese Americans. *Diabetes* 47:640-645; 1998.
72. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE: Human aging is associated with parallel reductions in insulin and amylin release. *Am J Physiol* 275:E785-E791; 1998.
73. Greenbaum CJ, Sears KL, Kahn SE, Palmer JP: The relationship of β -cell function and autoantibodies to progression and non-progression of subclinical type 1 diabetes. *Diabetes* 48:170-175; 1999.
74. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: a long recognized but under appreciated pathology of type 2 diabetes mellitus. *Diabetes*; 48:241-253; 1999.
75. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE: Heritability of pancreatic β -cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. *J Clin Endocrinol Metab* 84:1398-1403; 1999.
76. Andrikopoulos S, Verchere CB, Teague JC, Howell WM, Fujimoto WY, Wight TN, Kahn SE: Two novel immortal pancreatic β -cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. *Diabetes* 48:1962-1970; 1999.

77. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Porte D Jr, Schwartz MW: Reduced β -cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding. *Am J Physiol* 277:E659-E667; 1999.
78. Elbein SC, Wegner K, Kahn SE: Reduced β -cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. *Diabetes Care* 23:221-227; 2000.
79. Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS: Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. *J Clin Endocrinol Metab* 85:977-982; 2000.
80. Røder ME, Schwartz RS, Prigeon RL, Kahn SE: Reduced pancreatic B-cell compensation to the insulin resistance of aging: impact and implications for proinsulin and insulin levels. *J Clin Endocrinol Metab*, 85:2275-2280; 2000.
81. Verchere CB, D'Alessio DA, Prigeon RL, Hull RL, Kahn SE: The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells. *Diabetes* 49:1477-1484; 2000.
82. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW: Obesity induced by a high fat diet is associated with reduced brain insulin transport in dogs. *Diabetes* 49:1525-1533; 2000.
83. Kahn SE, Andrikopoulos S, Verchere CB, Wang F, Hull RL, Vidal J: Oophorectomy promotes islet amyloid formation in a transgenic mouse model of type 2 diabetes. *Diabetologia*, 43:1309-1312; 2000.
84. Andrikopoulos S, Verchere CB, Terauchi K, Kadowaki T, Kahn SE: β -cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. *Diabetes* 49:2056-2062; 2000.
85. Liao D, Shofer JB, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. *Diabetes Care* 24:39-44; 2001.
86. Purnell JQ, Kahn SE, Schwartz RS, Brunzell JD: Relationship of insulin sensitivity and apoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. *Arterioscler Thromb Vasc Biol* 21:567-572; 2001.
87. Kahn SE: The importance of β -cell failure in the development and progression of type 2 diabetes. *J Clin Endocrinol Metab* 86:4047-4058; 2001.
88. Halban PA, Kahn SE, Lernmark Å, Rhodes CJ: Gene and cell-replacement therapy in the treatment of type 1 diabetes: how high must the standards be set? *Diabetes* 50:2181-2191; 2001.
89. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE: Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. *Diabetes* 50:2514-2520; 2001.

90. Kahn SE, Montgomery B, Howell WM, Ligueros-Saylan M, Hsu C-H, Devineni D, McLeod JF, Horowitz AD, Foley JE: Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 86:5824-5829; 2001.
91. Knowles NG, Landchild MA, Fujimoto WY, Kahn SE: Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes mellitus. *Diabetes Care* 25:292-297; 2002.
92. Cnop M, Landchild M, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE: The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. *Diabetes* 51:1005-1015; 2002.
93. Liao D, Asberry PJ, Shofer JB, Callahan H, Matthys C, Boyko EJ, Leonetti D, Kahn SE, Austin M, Newell L, Schwartz RS, Fujimoto WY: Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. *Diabetes Care* 25:1504-1510; 2002.
94. Paoletta M, Kahn SE, Halban PA: Truncated (des-[27-31]) C-peptide is not a major secretory product of human islets. *Diabetologia* 45:1523-1527; 2002.
95. Sweet IR, Khalil G, Wallen AR, Steedman M, Schenkman KA, Reems JA, Kahn SE, Callis JB: Continuous measurement of oxygen consumption by pancreatic islets. *Diabetes Technol Ther* 4:661-672; 2002.
96. Nieves DJ, Cnop M, Retzlaff BM, Walden CE, Brunzell JD, Knopp RH, Kahn SE: The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. *Diabetes* 52:172-179; 2003.
97. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. *Diabetologia* 46:3-19; 2003.
98. Vidal J, Verchere CB, Andrikopoulos S, Wang F, Hull RL, Cnop M, Olin KL, LeBoeuf RC, O'Brien KD, Chait A, Kahn SE: The effect of apolipoprotein E deficiency on islet amyloid deposition in human islet amyloid polypeptide transgenic mice. *Diabetologia* 46:71-79; 2003.
99. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL, Kahn SE: Increased dietary fat promotes islet amyloid formation and β -cell secretory dysfunction. *Diabetes* 52:372-379; 2003.
100. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY: Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. *Diabetes Care* 26:650-655; 2003.
101. McNeely MJ, Boyko EJ, Leonetti DL, Kahn SE, Fujimoto WY: Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. *Diabetes Care* 26:758-763; 2003.

102. Potter-Perigo S, Hull RL, Tsoi C, Braun KR, Andrikopoulos S, Teague J, Verchere CB, Kahn SE, Wight TN: Proteoglycans synthesized and secreted by pancreatic islet β -cells bind human amylin. *Arch Biochem Biophys* 413:182-190; 2003.
103. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia* 46:459-469; 2003.
104. Knopp RH, Retzlaff B, Fish B, Walden C, Wallick S, Anderson M, Aikawa K, Kahn SE: Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. *Arterioscler Thromb Vasc Biol* 23:1437-1443; 2003.
105. Murdoch SJ, Kahn SE, Albers JJ, Brunzell JD, Purnell JQ: PTLP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity. *J Lipid Res* 44:1705-1712; 2003.
106. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY: Visceral adiposity and the prevalence of hypertension in Japanese Americans. *Circulation* 108:1718-1723; 2003.
107. Andrikopoulos S, Hull RL, Verchere CB, Wang F, Wilbur SM, Wight TN, Marzban L, Kahn SE: Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide. *Am J Physiol* 286:E418-E424; 2004.
108. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. *J Biol Chem* 279:12152-12162; 2004.
109. Kahn SE: Engineering a new β -cell: a critical venture requiring special attention to constantly changing physiological needs. *Semin Cell Dev Biol* 15:359-370; 2004.
110. Utzschneider KM, Carr DB, Barsness SM, Kahn SE, Schwartz RS: Diet-induced weight loss is associated with an improvement in β -cell function in older men. *J Clin Endocrinol Metab* 89:2704-2710; 2004.
111. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY: Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. *Ann Intern Med*, 140:992-1000; 2004.
112. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. *Diabetes* 53:2087-2094; 2004.
113. Hull RL, Westermark GT, Westermark P, Kahn SE: Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. *J Clin Endocrinol Metab* 89:3629-3643; 2004.

114. Utzschneider KM, Carr DB, Hull RL, Kodama K, Shofer JB, Retzlaff BM, Knopp RH, Kahn SE: Impact of intra-abdominal fat and age on insulin sensitivity and β -cell function. *Diabetes* 53:2867-2872; 2004.
115. Ioannou GN, Weiss NS, Boyko EJ, Kowdley KV, Kahn SE, Carithers RL, Dominitz JA: Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. *Clin Gastroenterol Hepatol* 3:67-74; 2005.
116. Carr DB, Utzschneider KM, Boyko EJ, Asberry PJ, Hull RL, Kodama K, Callahan HS, Matthys CC, Leonetti DL, Schwartz RS, Kahn SE, Fujimoto WY: A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improve insulin sensitivity but not β -cell function. *Diabetes* 54:340-347; 2005.
117. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP: Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. *Gastroenterology* 128:627-635; 2005.
118. Tong J, Fujimoto WY, Kahn SE, Weigle DS, McNeely MJ, Leonetti DL, Shofer JB, Boyko EJ: Insulin, C-peptide, and leptin concentrations predict increased visceral adiposity at 5- and 10 year follow-ups in nondiabetic Japanese Americans. *Diabetes* 54:985-990; 2005.
119. Retnakaran R, Hanley AJG, Raif N, Hirning CR, Connelly PW, Sermer M, Kahn SE, Zinman B: Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. *Diabetologia* 48:993-1001; 2005.
120. Tannock LR, O'Brien KD, Knopp RH, Retzlaff BM, Fish B, Wener MH, Kahn SE, Chait A: Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. *Circulation* 111:3058-3062; 2005.
121. Hull RL, Shen Z-P, Watts MR, Kodama K, Carr DB, Utzschneider KM, Zraika S, Wang F, Kahn SE: Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. *Diabetes* 54:2235-2244; 2005.
122. Hull RL, Kodama K, Utzschneider KM, Carr DB, Prigeon RL, Kahn SE: Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation. *Diabetologia* 48:1350-1358; 2005.
123. Hull RL, Watts MR, Kodama K, Shen Z, Utzschneider KM, Carr DB, Vidal J, Kahn SE: Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. *Am J Physiol* 289:E703-E709; 2005.
124. Andrikopoulos S, Massa CM, Aston-Mourney K, Funkat A, Fam BC, Hull RL, Kahn SE, Proietto J: Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. *J Endocrinology* 187:45-53; 2005.

125. Rasouli N, Hale T, Kahn SE, Spencer HJ, Elbein SC: Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic β -cell function in nondiabetic individuals. *J Clin Endocrinol Metab* 90:5825-5833; 2005.
126. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S: Preserved cognition in patients with early Alzheimer disease and amnesic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. *Am J Geriatr Pysch* 13:950-958; 2005.
127. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, Xiao Q, Mistry JS, Retzlaff BM, Knopp RH, Kahn SE: Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. *Diabetologia* 48:2330-2333; 2005.
128. Watson GS, Reger MA, Baker LD, McNeely MJ, Fujimoto WY, Kahn SE, Boyko EJ, Leonetti DL, Craft S: Effects of exercise and nutrition on memory in Japanese Americans with impaired glucose tolerance. *Diabetes Care* 29:135-136; 2006.
129. Utzschneider KM, Prigeon RL, Carr DB, Hull RL, Tong J, Shofer JB, Retzlaff BM, Knopp RH, Kahn SE: Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. *Diabetes Care* 29:356-362; 2006.
130. Krudys KM, Kahn SE, Vicini P: Population approaches to estimate minimal model indexes of insulin sensitivity and glucose effectiveness using full and reduced sampling schedules. *Am J Physiol* 291:E716-E723; 2006.
131. Utzschneider KM, Kahn SE: The role of insulin resistance in nonalcoholic fatty liver disease. *J Clin Endocrinol Metab* 91:4753-4761; 2006.
132. Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 444:840-846; 2006.
133. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Minimum waist and visceral fat values for identifying Japanese Americans at risk for the metabolic syndrome. *Diabetes Care* 30:120-127; 2007.
134. Tong J, Utzschneider KM, Carr DB, Zraika S, Udayasankar J, Gerchman F, Knopp RH, Kahn SE: Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects. *Diabetologia* 50:439-442; 2007.
135. Zraika S, Hull RL, Udayasankar J, Clark A, Utzschneider KM, Tong J, Gerchman F, Kahn SE: Identification of the amyloid-degrading enzyme neprilysin in mouse islets and potential role in islet amyloidogenesis. *Diabetes* 56:304-310; 2007.
136. Zraika S, Hull RL, Udayasankar J, Utzschneider KM, Tong J, Gerchman F, Kahn SE: Glucose- and time-dependence of islet amyloid formation *in vitro*. *Biochem Biophys Res Commun* 354:234-239; 2007. PMC1831460

137. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, Scherer PE, Boyko EJ, Fujimoto WY, Kahn SE: Progressive loss of β -cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. *Diabetes Care* 30:677-682; 2007.
138. Gerchman F, Tong J, Utzschneider KM, Hull RL, Zraika S, Udayasankar J, McNeely MJ, Andress DL, Leonetti DL, Boyko EJ, Fujimoto WY, Kahn SE: Superiority of the Modification of Diet in Renal Disease equation over the Cockcroft-Gault equation in screening for impaired kidney function in Japanese Americans. *Diabetes Res Clin Pract* 77:320-326; 2007. PMC1995414
139. Tong J, Boyko EJ, Utzschneider KM, McNeely MJ, Hayashi T, Carr DB, Wallace TM, Zraika S, Gerchman F, Leonetti DL, Fujimoto WY, Kahn SE: Intra-abdominal fat accumulation predicts the future development of the metabolic syndrome in Japanese Americans. *Diabetologia* 50:1156-1160; 2007.
140. Wallace TM, Utzschneider KM, Tong J, Carr DB, Zraika S, Bankson DD, Knopp RH, Kahn SE: Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat. *Diabetes Care* 30:2673-2678; 2007.
141. Hull RL, Zraika S, Udayasankar J, Kisilevsky R, Szarek WA, Wight TN, Kahn SE: Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. *Am J Physiol* 293:1586-1593; 2007. PMC2365901
142. Utzschneider KM, Prigeon RL, Tong J, Gerchman F, Carr DB, Zraika S, Udayasankar J, Montgomery B, Mari A, Kahn SE: Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. *Diabetologia* 50:2516-2525; 2007.
143. Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE: The dipeptidyl peptidase-4 inhibitor vildagliptin improves β -cell function and insulin sensitivity in subjects with impaired fasting glucose. *Diabetes Care* 31:108-113; 2008.
144. Kratz M, Purnell JQ, Breen PA, Thomas KK, Utzschneider KM, Carr DB, Kahn SE, Hughes JP, Rutledge EA, Van Yserloo B, Yukawa M, Weigle DS: Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipodystrophy. *J Clin Endocrinol Metab* 93:959-966; 2008. PMC2266944
145. Carr DB, Newton KM, Utzschneider KM, Tong J, Gerchman F, Kahn SE, Heckbert SR: Modestly elevated glucose levels during pregnancy are associated with a higher risk of future diabetes amongst women without gestational diabetes mellitus. *Diabetes Care* 31:1037-1039; 2008.
146. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. *Diabetes* 57:1269-1275; 2008.
147. Udayasankar J, Kodama K, Hull RL, Zraika S, Aston-Mourney K, Subramanian SL, Tong J, Faulenbach MV, Vidal J, Kahn SE: Amyloid formation results in recurrence of hyperglycemia following transplantation of human IAPP transgenic mouse islets. *Diabetologia* 52:145-153; 2009. PMC2734275

148. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY, Kahn SE: Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. *Diabetes Care* 32:335-341; 2009. PMC2628704
149. Purnell JQ, Kahn SE, Samuels MH, Brandon D, Loriaux DL, Brunzell JD: Enhanced cortisol production rates, free cortisol, and 11 β -HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. *Am J Physiol* 296:E351-E357; 2009. PMC2645022
150. Zraika S, Hull RL, Udayasankar J, Aston-Mourney K, Subramanian SL, Kisilevsky R, Szarek WA, Kahn SE: Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. *Diabetologia* 52:626-635; 2009. PMC2719780
151. Goedecke JH, Dave JA, Faulenbach MV, Utzschneider KM, Lambert EV, West S, Collins M, Olsson T, Walker BR, Seckl JR, Kahn SE, Levitt NS: Insulin response in relation to insulin sensitivity: an appropriate β -cell response in black South African women. *Diabetes Care* 32:860-865; 2009. PMC2719780
152. Kahn SE, Zraika S, Utzschneider KM, Hull RL: The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. *Diabetologia* 52:1003-1012; 2009. PMC2737455
153. Hull RL, Zraika S, Udayasankar J, Aston-Mourney K, Subramanian SL, Kahn SE: Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. *Diabetologia* 52:1102-1111; 2009. PMC2734275
154. Berman P, Collins M, Baumgarten I, Seoighe C, Jennings C, Joffe Y, Lambert EV, Levitt NS, Faulenbach MV, Kahn SE, Goedecke JH: Association between the 4 bp proinsulin gene insertion polymorphism (IVS-69) and body composition in black South African women. *Obesity* 17:1298-1300; 2009.
155. Goedecke JH, Levitt NS, Lambert EV, Utzschneider KM, Faulenbach MV, Dave J, West S, Victor H, Evans J, Olsson T, Walker BR, Seckl JR, Kahn SE: Differential effects of abdominal adipose tissue distribution on insulin sensitivity in black and white South African women. *Obesity* 17:1506-1512; 2009.
156. Gerchman F, Tong J, Utzschneider KM, Zraika S, Udayasankar J, McNeely MJ, Carr DB, Leonetti DL, Young BA, de Boer IH, Boyko EJ, Fujimoto WY, Kahn SE: Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. *J Clin Endocrinol Metab* 94:3781-3788; 2009. PMC2758725
157. Carr DB, Newton KM, Utzschneider KM, Tong J, Gerchman F, Kahn SE, Easterling TR, Heckbert SR: Preeclampsia and risk of developing subsequent diabetes. *Hypertens Pregnancy* 28:435-447; 2009.
158. Halban PA, German MS, Kahn SE, Weir GC: Current status of islet cell replacement and regeneration therapy. *J Clin Endocrinol Metab* 95:1034-1043; 2010. PMC2841538
159. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, Raleigh DP, Kahn SE: Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? *Diabetologia* 53:1046-1056; 2010. PMC3164873

160. Zraika S, Aston-Mourney K, Hull RL, Marek P, Green PS, Udayasankar J, Subramanian SL, Raleigh DP, Kahn SE: Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation. *J Biol Chem* 285:18177-18183; 2010. PMC2881741
161. Lee CG, Fujimoto WY, Brunzell JD, Kahn SE, McNeely MJ, Leonetti DL, Boyko EJ: Intra-abdominal fat accumulation is greatest at younger ages in Japanese-American adults. *Diabetes Res Clin Pract* 89:58-64; 2010. PMC2893258
162. Boyko EJ, Doheny RA, McNeely MJ, Kahn SE, Leonetti DL, Fujimoto WY: Latent class analysis of the metabolic syndrome. *Diabetes Res Clin Pract* 89:88-92; 2010. PMC2893282
163. Lima MMO, Pareja JC, MD, Alegre SM, Geloneze SR, Kahn SE, Astiarraga BD, Chaim EA, Geloneze B: Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. *J Clin Endocrinol Metab* 95:3871-3875; 2010.
164. Goedecke JH, Utzschneider K, Faulenbach MV, Rizzo M, Berneis K, Spinass GA, Dave JA, Levitt NS, Lambert EV, Olsson T, Kahn SE: Ethnic differences in serum lipoproteins and their determinants in South African women. *Metabolism* 59:1341-1350; 2010.
165. Utzschneider KM, Van de Lagemaat A, Faulenbach MV, Goedecke JH, Carr DB, Boyko EJ, Fujimoto WY, Kahn SE: Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes. *Obesity* 18:1781-1787; 2010.
166. Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, Tschöp MH, D'Alessio D: Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. *Diabetes* 59:2145-2151; 2010. PMC2927935
167. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll R, Mills KHG, Mok KH, Newsholme P, Nunez G, Yodoi J, Kahn SE, Lavelle EC, O'Neill LAJ: Activation of the Nlrp3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. *Nat Immunol* 11:897-904; 2010. PMC3103663
168. Hoofnagle AN, Wu M, Gosmanova AK, Becker JO, Wijsman EM, Brunzell JD, Kahn SE, Knopp RH, Lyons TJ, Heinecke JW: Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. *Arterioscler Thromb Vasc Biol* 30:2528-2534; 2010. PMC2988100
169. Carr DB, Newton KM, Utzschneider KM, Faulenbach M, Kahn SE, Easterling TR, Heckbert SR: Gestational diabetes or lesser degrees of glucose intolerance and risk of preeclampsia. *Hypertens Pregnancy* 30:153-163; 2011.
170. Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY: Greater hand-grip strength predicts a lower risk of developing type 2 diabetes over 10 years in leaner Japanese Americans. *Diabetes Res Clin Pract* 92:261-264; 2011.

171. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, Aston-Mourney KA, Carr DB, Westermark P, Westermark GT, Kahn SE, Hull RL: β -cell loss and β -cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. *Am J Pathol* 178:2632-2640; 2011. PMC3123989
172. Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Walter BK, Tsai E, Plymate SR, Postupna N, Wilkinson CW, Zhang J, Lampe J, Kahn SE, Craft S: Dietary intervention and cerebrospinal fluid biomarkers in amnesic mild cognitive impairment. *Arch Neurol* 68:743-752; 2011.
173. Aston-Mourney K, Hull RL, Zraika S, Udayasankar J, Subramanian SL, Kahn SE: Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. *Diabetologia* 54:1756–1765; 2011. PMC3220951
174. Gradmark A, Pomeroy J, Renström F, Steingra S, Persson M, Wright A, Bluck L, Domellöf M, Kahn SE, Mogren I, Franks PW: Physical activity, sedentary behaviors, and estimated insulin sensitivity and secretion in pregnant and non-pregnant women. *BMC Pregnancy Childbirth* 11:44; 2011. PMC3130709
175. Hoyer D, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Subcutaneous thigh fat area is unrelated to risk of type 2 diabetes in a prospective study of Japanese Americans. *Diabetologia* 54:2795-22800; 2011. PMC3667698
176. Paramsothy P, Knopp RH, Kahn SE, Retzlaff BM, Fish B, Ostlund RE Jr: Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity. *Am J Clin Nutr* 94:1182-1188; 2011. PMC3192472
177. Goedecke JH, Evans J, Keswell D, Stimson RH, Livingstone DEW, Hayes P, Adams K, Dave JA, West S, Victor H, Lambert EV, Walker BR, Seckl JR, Olsson T, Kahn SE: Reduced gluteal expression of adipogenic and lipogenic genes in black South African women is associated with obesity-related insulin resistance. *J Clin Endocrinol Metab* 96:E2029-E2033; 2011
178. Subramanian SL, Hull RL, Zraika S, Aston-Mourney K, Udayasankar J, Kahn SE: JNK activation mediates islet amyloid-induced beta-cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets. *Diabetologia* 55:166-174; 2012. PMC3249975
179. Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM, Kahn SE: Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β -cell function. *Diabetes Care* 35:1119-1125; 2012. PMC3329824
180. Smits MM, Boyko EJ, Utzschneider KM, Leonetti DL, McNeely MJ, Suvag S, Wright LA, Fujimoto WY, Kahn SE: Arm length is associated with type 2 diabetes in Japanese-Americans. *Diabetologia* 55:1679-1684; 2012. PMC3678981
181. Pomeroy J, Renström F, Gradmark AM, Mogren I, Persson M, Bluck L, Wright A, Kahn SE, Domellöf M, Franks PW: Maternal physical activity and insulin action in pregnancy and their relationships with infant body composition. *Diabetes Care* 36:267-269; 2013. PMC3554315

182. Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY: Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans. *Diabetes Care* 36:289-293; 2013. PMC3554282
183. De Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J: Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. *Kidney Int* 83:323-330; 2013. PMC3509239
184. Aston-Mourney K, Zraika S, Udaysankar J, Subramanian SL, Green PS, Kahn SE, Hull RL: Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. *J Biol Chem* 288:3553-3559; 2013. PMC3561574
185. Hayashi T, Boyko EJ, Sato KK, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Patterns of insulin concentration during the OGTT predict the risk of type 2 diabetes in Japanese Americans. *Diabetes Care* 36:1229-1235; 2013. PMC3631850
186. Zraika S, Koh D-S, Barrow BM, Lu B, Kahn SE, Andrikopoulos S: Neprilysin deficiency protects against fat-induced insulin secretory dysfunction by maintaining calcium influx. *Diabetes* 62:1593-1601; 2013. PMC3636612
187. Lima MMO, Pareja JC, Alegre SM, Geloneze SR, Kahn SE, Astiarraga BD, Chaim ÉA, Baracat J, Geloneze B: Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers. *Obesity* 21:E182-189; 2013.
188. Rhodes CJ, White MF, Leahy JL, Kahn SE: A direct autocrine action of insulin on β -cells: does it make physiological sense? *Diabetes* 62:2157-2163; 2013. PMC3712043
189. Smits MM, Woudstra P, Utzschneider KM, Tong J, Gerchman F, Faulenbach M, Carr DB, Aston-Mourney K, Chait A, Knopp RH, Meigs JB, EJ, Kahn SE: Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. *Ann Epidemiol* 23:415-421; 2013. PMC3778191
190. Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE, McCormick W, McCurry SM, Bowen JD, Larson EB: Glucose levels and risk of dementia. *N Engl J Med* 369:540-548; 2013. PMC3955123
191. Gujral UP, Narayan KMV, Kahn SE, Kanaya AM: The relative associations of β -cell function and insulin sensitivity with glycemic status in migrant Asian Indians in the United States: the MASALA Study. *J Diabetes Complications* 28:45-50; 2014. PMC3877179
192. Utzschneider KM, Largajolli A, Bertoldo A, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Kahn SE: Serum ferritin is associated with non-alcoholic fatty liver disease and decreased β -cell function in non-diabetic men and women. *J Diabetes Complications* 28:177-184; 2014. PMC3943487
193. Kahn SE, Cooper ME, Del Prato S: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present and future. *Lancet* 383:1068-1083; 2014. PMC4226760

194. Meier DT, Morcos M, Samarasekera T, Zraika S, Hull RL, Kahn SE: Islet amyloid formation is an important determinant for inducing islet inflammation in high fat fed human islet amyloid polypeptide transgenic mice. *Diabetologia* 57:1884-1888; 2014. PMC4267509
195. Phillips LS, Ratner RE, Buse JB, Kahn SE: We can change the natural history of type 2 diabetes. *Diabetes Care* 37:2668-2676; 2014. PMC4170125
196. Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M: Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. *Diabetes* 63:673-686; 2015. PMC4338588
197. Araneta MRG, Kanaya AM, Hsu W, Chang HK, Grandinetti A, Boyko EJ, Hayashi T, Kahn SE, Leonetti DL, McNeely MJ, Onishi Y, Sato KK, Fujimoto WY: Optimum BMI cut points to screen Asian Americans for type 2 diabetes. *Diabetes Care* 38:814-820; 2015. PMC4407753
198. Sullivan CA, Kahn SE, Fujimoto WY, Hayashi T, Leonetti DL, Boyko EJ: Change in intra-abdominal fat predicts the risk of hypertension in Japanese Americans. *Hypertension* 66:134-140; 2015. PMC4467450
199. Goedecke JH, Chorell E, Livingstone DE, Stimson RH, Hayes P, Adams K, Dave JA, Victor H, Levitt NS, Kahn SE, Seckl JR, Walker BR, Olsson T: Glucocorticoid receptor gene expression in adipose tissue and associated metabolic risk in black and white South African women. *Int J Obes* 39:303-311; 2015.
200. Kahn SE, Buse JB: Medications for type 2 diabetes: how will we be treating patients in fifty years? *Diabetologia* 58:1745-1739; 2015. PMC4499484
201. Meier DT, Entrup L, Templin AT, Hogan MF, Samarasekera T, Zraika S, Boyko EJ, Kahn SE: Determination of optimal sample size for quantification of β -cell area, amyloid area and β -cell apoptosis in isolated islets. *J Histochem Cytochem* 63:663-673; 2015. PMC4530400
202. Hwang YC, Hayashi T, Fujimoto WY, Kahn SE, Leonetti DL, McNeely MJ, Boyko EJ: Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype. *Int J Obes* 39:1365-1370; 2015. PMC4564328
203. Goedecke JH, Keswell D, Weinreich C, Fan J, Hauksson J, Victo H, Utschneider K, Levitt NS, Lambert EV, Kahn SE, Olsson T: Ethnic differences in hepatic and systemic insulin sensitivity and their associated determinants in obese black and white South African women. *Diabetologia* 58:2647-2652; 2015. PMC4668114
204. Hogan MF, Ravnskjaer K, Matsumura S, Huising MO, Hull RL, Kahn SE, Montminy M: Hepatic insulin resistance following chronic activation of the CREB coactivator CRTC2. *J Biol Chem* 290:25997-26006; 2015. PMC4646253
205. Marathe CS, Feinle-Bisset C, Pilichiewicz A, Lange K, Jones KL, Rayner CK, Kahn SE, Horowitz M: The duodenal glucose load impacts the oral disposition index in healthy subjects. *Diabet Med* 32:1500-1503; 2015.

206. Hwang YC, Hayashi T, Fujimoto WY, Kahn SE, Leonetti DL, McNeely MJ, Boyko EJ: Differential association between HDL subclasses and the development of type 2 diabetes in a prospective study of Japanese Americans. *Diabetes Care* 38:2100-2105; 2015. PMC4613920
207. Meier DT, Tu L-H, Zraika S, Hogan MF, Templin AT, Hull RL, Raleigh DP, Kahn SE: Matrix metalloproteinase-9 protects islets from amyloid-induced toxicity. *J Biol Chem* 290:30475-30485; 2015. PMC4683269
208. Hwang YC, Fujimoto WY, Kahn SE, Hayashi T, Leonetti DL, Boyko EJ: Increased visceral adipose tissue is an independent predictor for future development of atherogenic dyslipidemia. *J Clin Endocrinol Metab* 101:678-685; 2016.
209. De Boer IH, Zelnick L, Afkarian M, Ayers E, Curtin L, Himmelfarb J, Ikizler TA, Kahn SE, Utzschneider KM: Impaired glucose and insulin homeostasis in moderate-severe CKD. *J Am Soc Nephrol* 27:2861-2871; 2016.
210. Hogan MF, Meier DT, Zraika S, Templin AT, Mellati M, Hull RL, Leissring MA, Kahn SE: Inhibition of insulin-degrading enzyme does not increase islet amyloid deposition in vitro. *Endocrinology* 157:3462-3468; 2016.
211. Meier DT, Entrup L, Templin AT, Hogan MF, Mellati M, Zraika S, Hull RL, Kahn SE: The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. *Diabetologia* 59:2166-2171; 2016.
212. Bowlby W, Zelnick L, Henry C, Himmelfarb J, Kahn SE, Kestenbaum B, Robinson-Cohen, Utzschneider K, de Boer IH: Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. *BMC Nephrology* 17:187; 2016.
213. Ahmad I, Zelnick LR, Robinson NR, Hung AM, Kestenbaum B, Utzschneider KM, Kahn SE, de Boer IH: Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared to the hyperinsulinemic-euglycemic clamp. *Am J Physiol* 312:E175-E182; 2017.
214. Morton GJ, Muta K, Kaiyala KJ, Rojas JM, Scarlett JM, Matsen ME, Nelson JT, Acharya NK, Piccinini F, Stefanovski D, Bergman RN, Taborsly GJ Jr, Kahn SE, Schwartz MW: Evidence that the sympathetic nervous system elicits rapid, coordinated, and reciprocal adjustments of insulin secretion and insulin sensitivity during cold exposure. *Diabetes* 66:823-834; 2017.
215. Hwang Y-C, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ: Greater visceral abdominal fat is inversely associated with the conversion of prehypertension to normotension. *J Hypertens* 35:1213-1218; 2017.
216. Marathe CS, Rayner CK, Lange K, Bound M, Wishart J, Jones KL, Kahn SE, Horowitz M: Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance. *Physiol Rep* 5: pii: e13122; 2017 (DOI: 10.14814/phy2.13122).

217. Templin AT, Samarasekera T, Meier DT, Hogan MF, Mellati M, Crow MT, Kitsis RN, Zraika S, Hull RL, Kahn SE: Apoptosis repressor with caspase recruitment domain ameliorates amyloid-induced β -cell apoptosis and JNK pathway activation. *Diabetes*, in press.

Invited Editorials and Reviews

1. Kahn SE, Klaff LJ: The importance of metabolic control in diabetes mellitus. *S Afr J Cont Med Ed* 1:iii 15-23; 1983.
2. Kahn SE, Porte D Jr: Pathophysiology of non-insulin-dependent diabetes mellitus: implications for treatment. *Saudi Med J* 9:580-587; 1988.
3. Kahn SE, Porte D Jr: Islet dysfunction in non-insulin-dependent diabetes mellitus. *Am J Med* 85 (Suppl 5A):4-8; 1988.
4. Porte D Jr, Kahn SE: Pathophysiology of non-insulin-dependent diabetes mellitus: implications for treatment. *Il Diabete* 1:25-30; 1989.
5. Porte D Jr, Kahn SE: What geriatricians should know about diabetes mellitus. *Diabetes Care* 13 (Suppl 2):47-54; 1990.
6. Kahn SE, Schwartz RS, Porte D Jr, Abrass IB: The glucose intolerance of aging. Implications for intervention. *Hosp Pract* 26:29-38; 1991.
7. Porte D Jr, Kahn SE: Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment - an update. *Am J Med* 90 (Suppl 6A):8S-14S; 1991.
8. Porte D Jr, Kahn SE: The key role of islet dysfunction in type II diabetes mellitus. *Clin Invest Med* 18:247-254; 1995.
9. Kahn SE: Regulation of B-cell function in vivo: from health to disease. *Diabetes Rev* 4:372-389; 1996.
10. Schwartz MW, Kahn SE: Insulin resistance and obesity. *Nature* 402:860-861; 1999.
11. Kahn SE: The importance of the β -cell in the pathogenesis of type 2 diabetes mellitus. *Am J Med* 108 (Suppl 6A):2S-8S; 2000.
12. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen K, Kahn SE, Leonetti DL, McNeely MJ, Newell LL, Shofer JB, Wahl PW: Type 2 diabetes and the metabolic syndrome in Japanese Americans. *Diabetes Res Clin Pract* 50 (Suppl 2): S73-S76; 2000.
13. Kahn, SE, Prigeon RL, Schwartz RS, Fujimoto WY, Knopp RH, Brunzell JD, Porte D Jr: Obesity, body fat distribution, insulin sensitivity and islet β -cell function as explanations for metabolic diversity. *J Nutr* 131:354S-360S; 2001.
14. Porte D Jr, Kahn SE: β -cell dysfunction and failure in type 2 diabetes: potential mechanisms. *Diabetes* 50 (Suppl 1):S160-S163; 2001.

15. Hull RL, Verchere CB, Andrikopoulos S, Wang F, Vidal J, Kahn SE: Oophorectomy promotes islet amyloid formation in human islet amyloid polypeptide transgenic mice. *Diabetes* 50 (Suppl 1):S184-S185; 2001.
16. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen K-W, Kahn SE, Leonetti DL, McNeely MJ, Newell LL, Shofer JB, Tsunehara CH, Wahl PW: Preventing diabetes – applying pathophysiologic and epidemiologic evidence. *Br J Nutr* 84 (Suppl 2):S173-S176; 2001.
17. Kahn SE: Beta cell failure: causes and consequences. *Int J Clin Pract (Suppl 123)*:13-18; 2001.
18. Kahn SE: Insulin resistance and beta cell dysfunction: a dual therapeutic approach. *Eur J Clin Invest* 32 (Suppl 3):1-2; 2002.
19. Bergman RN, Finegood DT, Kahn SE: The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. *Eur J Clin Invest* 32 (Suppl 3):35-45; 2002.
20. Kahn SE: The importance of β -cell dysfunction in the pathogenesis of type 2 diabetes mellitus. *Harrison's Online*, McGraw Hill, 2002. (Accessed October 25, 2002, at http://www.harrisonsonline.com/server-java/Arknoide/amed/harrisons/ex_editorials/ed13353_p01.html)
21. Knopp RH, Retzlaff B, Aikawa K, Kahn SE: Management of patients with diabetic hyperlipidemia. *Am J Cardiol* 91 (Suppl):24E-28E; 2003.
22. Fonseca VA, Kahn SE: Of Hopes and DREAMS: the quest to prevent type 2 diabetes. *J Clin Endocrinol Metab* 91:4762-4763; 2006.
23. Kahn SE, Zinman B: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes. *Diabetes Care* 30:1672-1676; 2007.
24. Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM: An examination of β -cell function measures and their potential use for estimating β -cell mass. *Diabetes Obes Metab* 10 (Suppl 4):63-76; 2008.
25. Kahn SE, Cefalu WT: Glucose control, macro- and microvascular disease, and the Food and Drug Administration: Let's keep our eye on the ball. *J Clin Endocrinol Metab* 93:3727-3729; 2008.
26. Kahn SE: Glucose control in type 2 diabetes: still worthwhile and worth pursuing. *JAMA* 301:1590-1592; 2009.
27. Kahn SE, Utzschneider KM: What's next for diabetes prevention? *Diabetes Care* 34:1678-1680; 2011. PMC3120186
28. Fujimoto WY, Boyko EJ, Hayashi T, Kahn SE, Leonetti DL, McNeely MJ, Shuman WP: Risk factors for type 2 diabetes: lessons learned from Japanese Americans in Seattle. *J Diabetes Invest* 3:212-224; 2012. PMC3393109
29. Kahn SE, Suvag S, Wright LA, Utzschneider KM: Interactions between genetic background, insulin resistance and β -cell function. *Diabetes Obes Metab* 14 (Suppl 3):46-56; 2012.

30. Kahn SE: Quantifying β -cells in health and disease: the past, the present and the need. *Diabetes Care* 36:4-5; 2012. PMC3526199
31. Kahn SE: Incretin therapy and islet pathology: a time for caution. *Diabetes* 62:2178-2180; 2013. PMC3712079
32. de Boer IH, Kahn SE: SGLT2 inhibitors – sweet success for diabetic kidney disease? *J Am Soc Nephrol* 28:7-10; 2017.

Book Chapters and Other Publications

1. Davidson JS, Kahn SE, Rayner B, Levitt NS, Ames FR, Disler PB, Bonafede P: The medical care of prisoners and detainees (letter). *S Afr Med J* 64:116; 1983.
2. Kahn SE, Porte D Jr: Pathophysiology of islet dysfunction in non-insulin-dependent (type II) diabetes mellitus. In: *Diabetes 1988. Proceedings of the 13th International Diabetes Federation, Sydney, Australia*, RG Larkins, PZ Zimmet and DJ Chisholm, eds., Excerpta Medica, Amsterdam, ICS#800, 1989, p 479-483.
3. D Cameron, S Colagiuri, L Heding, C Köhl, A Ma, and R Mortimer, eds., Excerpta Medica, Hong Kong, 1989, p 10-14.
4. Kahn SE, Porte D Jr: Pathophysiology of islet dysfunction in non-insulin-dependent (type II) diabetes mellitus. In: *Non-Insulin-Dependent Diabetes Mellitus*. D Cameron, S Colagiuri, L Heding, C Köhl, A Ma, and R Mortimer, eds., Excerpta Medica, Hong Kong, 1989, p 10-14.
5. Kahn SE, Porte D Jr: Pathophysiology of type II diabetes mellitus: implications for treatment. In: *Diabetes Mellitus: Theory and Practice*, H Rifkin, and D Porte Jr, eds., Elsevier, New York, 1990, p 436-456.
6. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in type 2 diabetes. In: *Frontiers in Diabetes Research: Lessons from Animal Diabetes III*, E Shafrir, ed., Smith-Gordon, London, 1991, p 507-511.
7. Wallum BJ, Kahn SE, McCulloch DK, Porte D Jr: Insulin secretion in the normal and diabetic human. In: *The International Textbook of Diabetes Mellitus*, KGMM Alberti, RA DeFronzo, H Keen, and P Zimmet, eds., John Wiley and Sons, England, 1992, p 285-301.
8. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in type II diabetes. In: *Progress in Endocrinology. Proceedings of the 9th Int. Congress of Endocrinology, Nice, France*, R Mornex, C Jaffiol, and J Leclere, eds., Parthenon Publishing, England, 1993, p 800-803.
9. Kahn SE, Prigeon RL, Porte D Jr: Insulin and proinsulin in normal and diabetic humans. In: *Insulin Secretion and Pancreatic B-cell Research*, PR Flatt and S Lenzen, eds., Smith-Gordon, London, 1994, p 391-401.
10. Fujimoto WY, Kahn SE, Brunzell JB: Metabolic basis for coronary heart disease risk in central obesity and glucose intolerance. In: *Multiple Risk Factors in Cardiovascular Disease*, A Yamamoto, ed., Churchill Livingstone, Tokyo, 1994, p 189-192.

11. Verchere CB, D'Alessio DA, Kahn SE: Consequences of human islet amyloid polypeptide expression in transgenic mice. In: *Lessons from Animal Diabetes VI: 75th Anniversary of the Insulin Discovery*, E Shafir, ed., Birkhäuser, Boston, 1996, p 131-148.
12. Kahn SE, Porte D Jr: Pathophysiology of type II diabetes mellitus. In: *Diabetes Mellitus*, 5th edition, D Porte Jr and RS Sherwin, eds., Elsevier, New York, 1996, p 487-512.
13. Kahn SE: Assessment of B-cell function in humans: approach and interpretation. In: *Clinical Research in Diabetes and Obesity*, B Draznin and RA Rizza, eds., Humana Press, Totawa NJ, 1997, p 3-22.
14. Kahn SE, McCulloch DK, Porte D Jr: Insulin secretion in the normal and diabetic human. In: *The International Textbook of Diabetes Mellitus*, 2nd edition, KGMM Alberti, RA DeFronzo, H Keen, and P Zimmet, eds., John Wiley and Sons, England, 1997, p 337-353.
15. Kahn SE, Porte D Jr: β -cell dysfunction in type 2 diabetes: pathophysiologic and genetic bases. In: *The Metabolic and Molecular Bases of Inherited Disease*, 8th edition, CR Scriver, AL Beaudet, WS Sly, D Valle, B Childs, KW Kinzler and B Vogelstein, eds., McGraw-Hill, New York, 2001, p 1407-1431.
16. Vidal J, Kahn, SE: Regulation of insulin secretion in vivo. In: *Genetics of Diabetes Mellitus*, WL Lowe Jr, ed., Kluwer, Boston, 2001, p 109-131.
17. Kahn SE, Porte D Jr: The pathophysiology and genetics of type 2 diabetes mellitus. In: *Diabetes Mellitus*, 6th edition, D Porte Jr, RS Sherwin and AD Baron, eds., McGraw-Hill, New York, 2002, p 331-365.
18. Hull RL, Kahn SE: Islet amyloid in type 2 diabetes. In: *Diabetes Mellitus: A Fundamental and Clinical Text*, 3rd edition, D LeRoith, SI Taylor, and JM Olefsky, eds., Lippincott, Williams and Wilkins, Philadelphia, 2004, p 151-161.
19. Utzschneider KM, Porte D Jr, Kahn SE: Insulin secretion in the normal and diabetic human. In: *The International Textbook of Diabetes Mellitus*, 3rd edition, RA DeFronzo, E Ferrannini, H Keen, and P Zimmet, eds., John Wiley and Sons, Chichester England, 2004, p 139-151.
20. Utzschneider KM, Kahn SE: β -cell dysfunction in type 2 diabetes. In: *The International Textbook of Diabetes Mellitus*, 3rd edition, RA DeFronzo, E Ferrannini, H Keen, and P Zimmet, eds., John Wiley and Sons, Chichester England, 2004, p 375-385.
21. Chait A, Lewis K, Tannock L, O'Brien K, Retzlaff B, Kahn S, Knopp R, Wight T: Nutrition and inflammation: role of dietary cholesterol. In: *Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium*, Kyoto, Japan, Y Matsuzawa, T Kita, R Nagai, T Teramoto, eds., Elsevier, Amsterdam, ICS#1262, 2004, p 313-316.
22. Røder ME, Kahn SE: Suppression of β -cell secretion by somatostatin does not fully reverse the disproportionate proinsulinemia of type 2 diabetes. *Diabetes* 53 (Suppl 3): S22-S25; 2004.

23. Kahn SE, Porte D Jr: The pathophysiology and genetics of type 2 diabetes mellitus. In: The Diabetes Mellitus Manual, SE Inzucchi, D Porte Jr, RS Sherwin and AD Baron, eds., McGraw-Hill, New York, 2004, p 51-75.
24. Porte D Jr, Kahn SE: New and old thoughts on hyperproinsulinemia and amyloid in type 2 diabetes. In: Commentaries on Perspectives in Diabetes – Volume 1 (1988-1992), RP Robertson, ed., American Diabetes Association, Alexandria, VA, 2006, p 70-71.
25. Kahn SE, Andrikopoulos S, Hull RL, Verchere CB: Islet amyloid: a long recognized but now more appreciated pathological feature of type 2 diabetes mellitus. In: Commentaries on Perspectives in Diabetes – Volume 3 (1998-2002), RP Robertson, ed., American Diabetes Association, Alexandria, VA, 2007, p 112-114.
26. Halban PA, Kahn SE, Lernmark A, Rhodes CJ: β -cell replacement therapy: a roadmap with milestones but no shortcuts. In: Commentaries on Perspectives in Diabetes – Volume 3 (1998-2002), RP Robertson, ed., American Diabetes Association, Alexandria, VA, 2007, p 293-294.
27. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Response to Oda E re Minimum waist and visceral fat values for identifying Japanese Americans at risk for the metabolic syndrome. Response to Oda. *Diabetes Care* 30: e41; 2007 (DOI: 10.2337/dc07-0207).
28. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY, Kahn SE: Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Response to DeFronzo and Abdul-Ghani. *Diabetes Care* 32:e87; 2009 (DOI: 10.2337/dc09-0729). PMC2628704
29. Goedecke JH, Lambert EV, Levitt NS, Olsson T, Seckl JR, Walker BR, Kahn SE: Insulin response in relation to insulin sensitivity: an appropriate β -cell response in black South African women. Response to Joffe and Distiller. *Diabetes Care* 32:e124; 2009 (DOI: 10.2337/dc09-1216). PMC2671086
30. Utzschneider KM, Kahn SE: Insulin action and beta-cell function: role in metabolic regulation. In: *Metabolic Risk for Cardiovascular Disease*, 1st edition, RH Eckel, ed., Wiley-Blackwell, Oxford, 2011, p 1-17.
31. Eckel RH*, Kahn SE*, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, Smith RJ, Smith SR: Obesity and type 2 diabetes: what can be unified and what needs to be individualized? *Diabetes Care* 34:1424-1430; 2011 PMC3114323 and *J Clin Endocrinol Metab* 96:1654-1663; 2011. (* contributed equally) PMC3206399
32. Suvag S, Utzschneider KM, Kahn SE: Treatment with thiazolidinediones. In: *The Metabolic Syndrome – Pharmacology and Clinical Aspects*, H Beck-Nielsen, ed., Springer Verlag, Vienna, 2013, p 117-146.
33. Heine RJ, Yki-Järvinen H, Kahn SE, van Raalte DH: Michaela Diamant, 11 April 1962 - 9 April 2014. *Diabetologia* 57:1271-1271; 2014.

34. Hull RL, Kahn SE: Pancreatic morphology in normal and diabetic states. In: The International Textbook of Diabetes Mellitus, 4th edition, RA DeFronzo, E Ferrannini, G Alberti, and P Zimmet, eds., John Wiley and Sons, Chichester England, in press.
35. Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M: Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Response to Zaccardi, Webb, Khunti and Davies, and Taegtmeier, Beauloye, Harmancey and Hue. *Diabetes* 64:e38-e39; 2015 (DOI: 10.2337/ dbi15-0002).
36. Cefalu WT, Buse JB, Tuomilehto J, Felming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE: Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a Diabetes Care editors' expert forum. *Diabetes Care* 39:1186-1201; 2016. Response: *Diabetes Care* 40:e23-e24; 2017.
37. Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC: Diabetes Care: "Taking It to the Limit One More Time". *Diabetes Care* 40:3-6; 2017.

A Diabetes Outcome Progression Trial (ADOPT) Publications

1. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI: A Diabetes Outcome Progression Trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. *Diabetes Care* 25:1737-1743; 2002.
2. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI, ADOPT Study Group: Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. *Diabetes* 53: 3193-3200; 2004.
3. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC, ADOPT Study Group: Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. *Diabetes* 55:2357-2364; 2006.
4. Viberti G, Lachin JM, Holman RR, Zinman B, Haffner SM, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH, ADOPT Study Group: A Diabetes Outcome Progression Trial (ADOPT): Baseline characteristics of type 2 diabetic patients in North America and Europe. *Diabetic Medicine* 23:1289-1294; 2006.
5. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 355:2427-2443; 2006. (Erratum 356:1387-1388; 2007).
6. Kahn SE, Viberti G, ADOPT Steering Committee: Glycemic durability of monotherapy for diabetes (letter). *N Engl J Med* 356:1380; 2007.

7. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G, ADOPT Study Group: Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 31:845-851; 2008.
8. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B, ADOPT Study Group: Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 33:177-183; 2010. PMC2797969
9. Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Aftring RP, Paul G, Viberti G, Kahn SE, ADOPT Study Group: Effect of rosiglitazone, metformin and glyburide on bone biomarkers in patients with type 2 diabetes. *J Clin Endocrinol Metab* 95:134-142; 2010.
10. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, ADOPT Study Group and RECORD Steering Committee: Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. *Diabetologia* 53:1838-1845; 2010. PMC2910882
11. Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR, ADOPT Study Group: Effects of rosiglitazone, glyburide and metformin on β -cell function and insulin sensitivity in ADOPT. *Diabetes* 60:1552-1560; 2011. PMC3292330
12. Viberti G, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, , Holman RR, Kahn SE, ADOPT Study Group: Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. *Clin J Am Soc Nephrol* 6:1032-1040; 2011.
13. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Plüddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomized clinical trials. *Diabetologia* 55:2593-2603; 2012.

Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (CAROLINA) Study Group Publications

1. Rosenstock J, Marx N, Johansen OE, Woerle H-J, CAROLINA Steering Committee: Cardiovascular effects of diabetes drugs: making the Dark Side brighter with CAROLINA (letter). *Ann Intern Med* 158:499; 2013.
2. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle H-J: Cardiovascular outcome trials in type 2 diabetes: rationale for the active comparator CAROLINA Trial. *Diab Vasc Dis Res* 10:289-301; 2013.
3. Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ: Design and baseline characteristics of the

CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA). *Diab Vasc Dis Res* 12:164-74; 2015.

Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS)
Publications

1. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. *Diabetes Care* 22:623-634; 1999.
2. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: evaluation and management of diabetes (letter). *Diabetes Care* 22:1757-1758; 1999.
3. Fujimoto WY, The Diabetes Prevention Program Research Group: Background and recruitment data for the U.S. Diabetes Prevention Program. *Diabetes Care* 23 (Suppl 2):B11-B13; 2000.
4. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: Baseline characteristics of the randomized cohort. *Diabetes Care* 23:1619-1629; 2000.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393-403; 2002.
6. Rubin RR, Fujimoto WY, Marrero DG, Brenneman T, Charleston JB, Edelstein SL, Fisher EB, Jordan R, Knowler WC, Lichterman LC, Prince M, Rowe PM, The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: recruitment methods and results. *Control Clin Trials* 23:157-171; 2002.
7. Knowler WC, The Diabetes Prevention Program Research Group: Diabetes prevention (letter). *N Engl J Med* 346:1830; 2002.
8. Wylie-Rosett J, Delahanty L, The Diabetes Prevention Program Research Group: An integral role of the dietitian: implications of the Diabetes Prevention Program. *J Am Diet Assoc* 102:1065-1068; 2002.
9. The Diabetes Prevention Program Research Group: Hypertension, insulin and proinsulin in participants with impaired glucose tolerance. *Hypertension* 40:679-686; 2002.
10. Delahanty LM, Meigs JB, Hayden D, Williamson DA, Nathan DM, The Diabetes Prevention Program Research Group: Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program. *Diabetes Care* 25:1992-1998; 2002.
11. The Diabetes Prevention Program Research Group*: The Diabetes Prevention Program: description of lifestyle intervention. *Diabetes Care* 25:2165-2171; 2002.
12. The Diabetes Prevention Program Research Group: Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. *Diabetes Care* 26:36-47; 2003.
13. The Diabetes Prevention Program Research Group*: Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. *Diabetes Care* 26:977-980; 2003.

14. The Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. *Diabetes Care* 26:2518-2523; 2003.
15. Molitch ME, The Diabetes Prevention Program Research Group*: Withdrawal from metformin in the Diabetes Prevention Program (letter). *Diabetes Care* 26:2702-2703; 2003.
16. Molitch ME, Fujimoto WY, Hamman RF, Knowler WC, The Diabetes Prevention Program Research Group: The Diabetes Prevention Program and its global implications. *J Am Soc Nephrol* 14 (Suppl 2):S103-S107; 2003.
17. Nathan DM, Hamman RF, Garfield S, Brenneman A, Fowler SF, Knowler WC, The Diabetes Prevention Program Research Group: Preventing Type 2 Diabetes: The Diabetes Prevention Program. In: *Diabetes Mellitus: A Fundamental and Clinical Text*, 3rd edition, D LeRoith, SI Taylor, and JM Olefsky, eds., Lippincott, Williams and Wilkins, Philadelphia, 2004, p 1077-1084.
18. The Diabetes Prevention Program Research Group: Achieving weight and activity goals amongst Diabetes Prevention Program lifestyle participants. *Obes Res* 12:1426-1434; 2004.
19. Mayer-Davis EJ, Sparks KC, Hirst K, Costacou T, Lovejoy JC, Regensteiner JG, Hoskin MA, Kriska AM, Bray GA, The Diabetes Prevention Program Research Group: Dietary intake in the Diabetes Prevention Program cohort: baseline and 1-year post-randomization. *Ann Epidemiol* 14: 763-772; 2004.
20. The Diabetes Prevention Program Research Group: Strategies to identify adults at high risk for type 2 diabetes: The Diabetes Prevention Program. *Diabetes Care* 28:138-144; 2005.
21. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE, The Diabetes Prevention Program Research Group: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. *Ann Intern Med* 142:323-332; 2005.
22. The Diabetes Prevention Program Research Group*: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. *Diabetes* 54:1150-1156, 2005.
23. The Diabetes Prevention Program Research Group: Depression symptoms and antidepressant medication use in the Diabetes Prevention Program participants. *Diabetes Care* 28:830-837, 2005.
24. The Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular risk factors in the Diabetes Prevention Program. *Diabetes Care* 28:888-894, 2005.
25. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, The Diabetes Prevention Program Research Group: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. *Ann Intern Med* 142:611-619; 2005.

26. The Diabetes Prevention Program Research Group: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. *Diabetes* 54:1566-1572; 2005.
27. The Diabetes Prevention Program Research Group*: Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: Effects of lifestyle intervention and metformin. *Diabetes* 54:2404-2414; 2005.
28. The Diabetes Prevention Program Research Group: Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the Diabetes Prevention Program. *Diabetes Care* 28:2472-2479, 2005.
29. Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y, Vittinghoff E, Kanaya AM, The Diabetes Prevention Program Research Group: Lifestyle intervention is associated with lower prevalence of urinary incontinence: The Diabetes Prevention Program. *Diabetes Care* 29:385-390; 2006.
30. Ratner RE, The Diabetes Prevention Program Research Group: An update on the Diabetes Prevention Program. *Endocr Pract* 12 (Suppl 1):20-24; 2006.
31. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME, The Diabetes Prevention Program Research Group: The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. *Diabetes Care* 29:914-919; 2006.
32. Kriska AM, Edelstein SL, Hamman RF, Otto A, Bray GA, Mayer-Davis EJ, Wing RR, Horton ES, Haffner SM, Regensteiner JG, The Diabetes Prevention Program Research Group: Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. *Med Sci Sports Exerc* 38:826-832; 2006.
33. Delahanty LM, Conroy MB, Nathan DM, The Diabetes Prevention Program Research Group: Psychological predictors of physical activity in the Diabetes Prevention Program. *J Am Diet Assoc* 106:698-705; 2006.
34. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D, The Diabetes Prevention Program Research Group: *TCF7L2* polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N Engl J Med* 355:241-250; 2006. PMC3144193
35. Walker EA, Molitch M, Kramer MK, Kahn SE, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J, The Diabetes Prevention Program Research Group: Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. *Diabetes Care* 29:1997-2002; 2006.
36. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J, The Diabetes Prevention Program Research Group: Effect of weight loss with lifestyle intervention on risk of diabetes. *Diabetes Care* 29:2102-2107; 2006.
37. The Diabetes Prevention Program Research Group: The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. *J Gerontol A Biol Sci Med* 61:1075-1081; 2006.

38. The Diabetes Prevention Program Research Group: Relationship of body size and shape to the development of diabetes in the Diabetes Prevention Program. *Obesity* 14:2107-2117; 2006.
39. The Diabetes Prevention Research Group: The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet Med* 24:137-144; 2007.
40. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan DM, Altshuler D, The Diabetes Prevention Program Research Group: Type 2 diabetes-associated missense polymorphisms *KCNJ11* E23K and *ABCC8* A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. *Diabetes* 56:531-536; 2007. PMC2267937
41. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM, The Diabetes Prevention Research Group: Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. *Diabetes* 56:1153-1159; 2007. PMC2533728
42. Florez JC, Jablonski K, Sun MW, Bayley N, Kahn SE, Shamon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D, The Diabetes Prevention Program Research Group: Effects of the type 2 diabetes-associated *PPARG* P12A polymorphism on progression to diabetes and response to troglitazone. *J Clin Endocrinol Metab* 92:1502-1509; 2007. PMC2267936
43. Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, Hanson R, Hill JO, Hubbard V, Stamm E, Pi-Sunyer X, The Diabetes Prevention Program Research Group: Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. *Diabetes* 56:1680-1685; 2007.
44. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E, The Diabetes Prevention Program Research Group: Differences in A1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. *Diabetes Care* 30:2453-2457; 2007. PMC2373980
45. Hoerger TJ, Hicks KA, Sorenson SW, Herman WH, Ratner RE, Ackermann RT, Zhang P, Englegau MM, The Diabetes Prevention Program Research Group: The cost-effectiveness of screening for prediabetes among overweight U.S. adults. *Diabetes Care* 30:2874-2879; 2007.
46. Nathan DM, The Diabetes Prevention Program Research Group: Diabetic retinopathy without diabetes (letter). *Diabet Med* 24:1174-1175; 2007.
47. Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC, The Diabetes Prevention Program Research Group: The Pro12Ala variant at the peroxisome proliferator-activated receptor γ gene and change in obesity-related traits in the Diabetes Prevention Program. *Diabetologia* 50:2451-2460; 2007. PMC2373986
48. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC, The Diabetes Prevention Program Research Group: Elevated depression symptoms, antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program. *Diabetes Care* 31:420-426; 2008. PMC2373986

49. Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Franks PW, Altshuler D, Knowler WC, The Diabetes Prevention Program Research Group: Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. *Diabetologia* 51:451-457; 2008. PMC2483955
50. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R, The Diabetes Prevention Program Research Group: Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. *Diabetes* 57:980-986; 2008. PMC2529455
51. Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX, The Diabetes Prevention Program Research Group: Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. *Am J Clin Nutr* 87:1212-1218; 2008. PMC2573045
52. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM, The Diabetes Prevention Program Research Group: The prevention of type 2 diabetes. *Nat Clin Pract Endocrinol Metab* 4:382-393; 2008. PMC2573045
53. Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E, The Diabetes Prevention Program Research Group: Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. *Diabetes Care* 31:1416-1421; 2008. PMC2453677
54. Moore AF, Jablonski KA, McAteer JB, Pollin TI, Franks PW, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC, The Diabetes Prevention Program Research Group: Extension of type 2 diabetes genome-wide association scan results in the Diabetes Prevention Program. *Diabetes* 57:2503-2510; 2008. PMC2518503
55. Franks PW, Jablonski KA, Delahanty LM, McAteer JB, Kahn SE, Knowler WC, Florez JC, The Diabetes Prevention Program Research Group: Assessing gene-treatment interactions at the *FTO* and *INSIG2* loci on obesity-related traits in the Diabetes Prevention Program. *Diabetologia* 51:2214-2223; 2008. PMC2947367
56. Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan V, Barrett-Connor E, Watson K, Knowler WC, Horton ES, The Diabetes Prevention Program Research Group: Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. *Diabetes Care* 31:2344-2348; 2008. PMC2584193
57. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE, The Diabetes Prevention Program Research Group: Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* 93:4774-4779; 2008. (Selected for the "International Award for Excellence in Published Clinical Research in The Journal of Clinical Endocrinology and Metabolism"). PMC2626441
58. Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, Hoskin MA, Knowler WC, Ma Y, The Diabetes Prevention Program Research Group: First versus repeat treatment

- with a lifestyle intervention program: attendance and weight loss outcomes. *Int J Obes* 32:1537-1544; 2008. PMC2574826
59. Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, Kahn SE, Kitabchi AE, Hanson RL, Knowler WC, Florez JC, The Diabetes Prevention Program Research Group: The association of *ENPP1* K121Q with diabetes incidence is abolished by lifestyle modification in the Diabetes Prevention Program. *J Clin Endocrinol Metab* 94:449-455; 2009. PMC2646511
 60. Ma Y, Temprosa M, Fowler S, Prineas RJ, Montez MG, Brown-Friday J, Carrion-Petersen ML, Whittington T, The Diabetes Prevention Program Research Group: Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting. *Am J Hypertens* 22:263-266; 2009. PMC2699679
 61. The Diabetes Prevention Program Research Group: Changes in albumin excretion in the Diabetes Prevention Program. *Diabetes Care* 32:720-725; 2009. PMC2660489
 62. Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, Price D, The Diabetes Prevention Program Research Group: Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: The Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. *Diabetes Care* 32:726-732; 2009. PMC2660486
 63. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF, Diabetes Prevention Program Research Group: Regression from pre-diabetes to normal glucose regulation in the Diabetes Prevention Program. *Diabetes Care* 32:1583-1588; 2009. PMC2732165
 64. Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL, Diabetes Prevention Program Research Group: Alcohol consumption and diabetes risk on the Diabetes Prevention Program. *Am J Clin Nutr* 90:595-601; 2009. PMC2728644
 65. The Diabetes Prevention Program Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 374; 1677-1686; 2009. PMC3135022
 66. Ackermann RT, Edelstein SL, Narayan VKM, Zhang P, Engelgau MM, Herman WH, Marrero DG, Diabetes Prevention Program Research Group: Changes in health state utilities with change in body mass in the Diabetes Prevention Program. *Obesity* 17:2176-2181; 2009. PMC3135001
 67. Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC, The Diabetes Prevention Program Research Group: Effects of metformin and weight loss on serum alanine aminotransferase activity in the Diabetes Prevention Program. *Obesity* 18:1762-1767; 2010. PMC3135003
 68. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D, Florez JC, The Diabetes Prevention Program Research Group: Common variants in 40 genes assessed for diabetes incidence and response to metformin and

- lifestyle intervention in the Diabetes Prevention Program. *Diabetes* 59:2672-2681; 2010. PMC3279522
69. Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, Knowler WC, The Diabetes Prevention Program Research Group: Antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. *Diabetes Care* 33:2549-2551; 2010. PMC2992187
 70. Hivert M-F, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, The DIAGRAM Consortium, Meigs JB, Altshuler D, Knowler WC, Florez JC, The Diabetes Prevention Program Research Group: Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. *Diabetes* 60:1340-1348; 2011. PMC3064108
 71. Pollin TI, Jablonski KA, McAteer JB, Saxena R, Kathiresan S, Kahn SE, Goldberg RB, Altshuler D, Florez JC, The Diabetes Prevention Program Research Group: Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the *GCKR* Pro446Leu polymorphism. *J Clin Endocrinol Metab* 96:E1142-E1147; 2011. PMC3205512
 72. Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E, The Diabetes Prevention Program Research Group: Menopause and risk of diabetes in the Diabetes Prevention Program. *Menopause* 18:857-868; 2011. PMC3500880
 73. Majithia AR, Jablonski KA, McAteer JB, Mather KJ, Goldberg RB, Kahn SE, Florez JC, The Diabetes Prevention Program Research Group: Association of the *SLC30A8* missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. *Diabetologia* 54:2570-2574; 2011. PMC3444290
 74. McCaffery JM, Jablonski KA, Franks PW, Dagogo-Jack S, Wing RR, Knowler WC, Delahanty L, Dabelea D, Hamman R, Shuldiner AR, Florez JC, The Diabetes Prevention Program Research Group: *TCF7L2* polymorphism, weight loss and proinsulin:insulin ratio in the Diabetes Prevention Program. *PLoS One* 6:e21518; 2011. PMC3144193
 75. Florez H, Ma Y, Crandall JP, Perreault L, Marcovina SM, Bray GA, Saudek CD, Barrett-Connor E, Knowler WC, The Diabetes Prevention Program Research Group: Parental longevity and diabetes risk in the Diabetes Prevention Program. *J Gerontol A Biol Sci Med Sci* 66A:1211-1217; 2011. PMC3193521
 76. Kilpelainen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, Ahmad T, Mora S, Kaakinen M, Sandholt CH, Holzapfel C, Autenrieth CS, Hypponen E, Cauchi S, He M, Kutalik Z, Kumari M, Stancakova A, Meidtner K, Balkau B, Tan JT, Mangino M, Timpson NJ, Song Y, Zillikens MC, Jablonski KA, Garcia ME, Johansson S, Bragg-Gresham JL, Wu Y, van Vliet-Ostaptchouk JV, Onland-Moret NC, Zimmermann E, Rivera NV, Tanaka T, Stringham HM, Silbernagel G, Kanoni S, Feitosa MF, Snitker S, Ruiz JR, Metter J, Larrad MT, Atalay M, Hakanen M, Amin N, Cavalcanti-Proenca C, Grontved A, Hallmans G, Jansson JO, Kuusisto J, Kahonen M, Lutsey PL, Nolan JJ, Palla L, Pedersen O, Perusse L, Renstrom F, Scott RA, Shungin D, Sovio U, Tammelin TH, Ronnema T, Lakka TA, Uusitupa M, Rios MS, Ferrucci L, Bouchard C, Meirhaeghe A, Fu M, Walker M, Borecki IB, Dedoussis GV, Fritsche A, Ohlsson C, Boehnke M, Bandinelli S, van Duijn CM, Ebrahim S,

- Lawlor DA, Gudnason V, Harris TB, Sorensen TI, Mohlke KL, Hofman A, Uitterlinden AG, Tuomilehto J, Lehtimaki T, Raitakari O, Isomaa B, Njolstad PR, Florez JC, Liu S, Ness A, Spector TD, Tai ES, Froguel P, Boeing H, Laakso M, Marmot M, Bergmann S, Power C, Khaw KT, Chasman D, Ridker P, Hansen T, Monda KL, Illig T, Jarvelin MR, Wareham NJ, Hu FB, Groop LC, Orho-Melander M, Ekelund U, Franks PW, Loos RJ: Physical activity attenuates the influence of FTO variants on obesity risk: A meta-analysis of 218,166 adults and 19,268 children. *PLoS Med* 8: e1001116; 2011. PMC3206047
77. Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, Kahn SE, Knowler WC, Florez JC, Franks PW, The Diabetes Prevention Program Research Group: Genetic predictors of weight loss and weight regain following intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. *Diabetes Care* 35:363-266; 2012. PMC3263869
78. Pittas AG, Nelson J, Mitri J, Hillmann W, Garganta C, Nathan DM, Hu FB, Dawson-Hughes B, The Diabetes Prevention Program Research Group: Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: An ancillary analysis in the Diabetes Prevention Program. *Diabetes Care* 35:565-573; 2012. PMC3322702
79. The Diabetes Prevention Program Research Group: The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS. *Diabetes Care* 35:723-730; 2012. PMC3308273
80. The Diabetes Prevention Program Research Group: Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. *Diabetes Care* 35:731-737; 2012. PMC3308305
81. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, The Diabetes Prevention Program Research Group: **Effect of** regression from pre-diabetes to normal glucose regulation is associated with long-term reduction in diabetes risk: Results from the Diabetes Prevention Program Outcomes Study. *Lancet* 379:2243-2251; 2012. PMC3555407
82. Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, Barrett-Connor E, Knowler WC, Shuldiner AR, Pollin TI, The Diabetes Prevention Program Research Group: The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. *Diabetes Care* 35:1864-1867; 2012. PMC3425006
83. Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW, The Diabetes Prevention Program Research Group: Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: The Diabetes Prevention Program. *PLoS Genet* 8:e1002895; 2012. PMC3431328
84. Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC, Shuldiner AR, Pollin TI, Knowler WC, The Diabetes Prevention Program Research Group: Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. *PLoS One* 7: e44424; 2012. PMC3439414

85. Kim C, Kong S, Laughlin GA, Golden SH, Mather KJ, Nan B, Edelstein SL, Randolph JF Jr, Labrie F, Buschur E, Barrett-Connor E, The Diabetes Prevention Program Research Group: Endogenous sex hormone changes in postmenopausal women in the Diabetes Prevention Program. *J Clin Endocrinol Metab* 97:2853-2861; 2012. PMC3410266
86. Kim C, Golden SH, Mather KJ, Laughlin GA, Kong S, Nan B, Barrett-Connor E, Randolph JF Jr, The Diabetes Prevention Program Research Group: Racial/ethnic differences in sex hormone levels among postmenopausal women in the Diabetes Prevention Program. *J Clin Endocrinol Metab* 97:4051-4060; 2012. PMC3485611
87. Mather KJ, Christophi CA, Jablonski KA, Knowler WC, Goldberg RB, Kahn SE, Spector T, Dastani Z, Waterworth D, Richards JB, Funahashi T, Pi-Sunyer FX, Pollin TI, Florez JC, Franks PW, The Diabetes Prevention Program Research Group: Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program. *Diabet Med* 29:1579-1588; 2012. PMC3499646
88. Florez H, Pan Q, Ackermann RT, Marrero DG, Barrett-Connor E, Delahanty L, Kriska A, Saudek CD, Goldberg RB, Rubin RR, The Diabetes Prevention Program Research Group: Impact of lifestyle intervention and metformin on health-related quality of life: the Diabetes Prevention Program Randomized Trial. *J Gen Intern Med* 27:1594-1601; 2012. PMC3509296
89. Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, Mather KJ, Marcovina SM, Montez M, Ratner RE, Saudek CD, Sherif H, Watson KE, The Diabetes Prevention Program Research Group: Long term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. *Diabet Med* 30:46-55; 2013. PMC3524372
90. Delahanty LM, Peyrot M, Shrader PJ, Williamson DA, Meigs JB, Nathan DM, The Diabetes Prevention Program Research Group: Pretreatment, psychological, and behavioral predictors of weight outcomes among lifestyle intervention participants in the Diabetes Prevention Program. *Diabetes Care* 36:34-40; 2013. PMC3526204
91. Price DW, Ma Y, Rubin RR, Perreault L, Bray GA, Marrero D, Knowler WC, Barrett-Connor E, Lacoursiere DY, The Diabetes Prevention Program Research Group: Depression as a predictor of weight regain among successful weight losers in the Diabetes Prevention Program. *Diabetes Care* 36:216-221; 2013. PMC3554307
92. Christophi CA, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamon H, Barrett-Connor E, Kahn SE, The Diabetes Prevention Program Research Group: Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults. *J Diabetes Complications* 27:150-157; 2013. PMC3594066
93. Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, Foulkes MA, Zhang P, Saudek CD, Brown MB, The Diabetes Prevention Program Research Group: Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. *Am J Manag Care* 19:194-202; 2013.
94. Kim C, Kong S, Laughlin GA, Golden SH, Mather KJ, Nan B, Randolph JF Jr, Edelstein SL, Labrie F, Buschur E, Barrett-Connor E, The Diabetes Prevention Program Research Group: Reductions in

- glucose among postmenopausal women who use and do not use estrogen therapy. *Menopause* 20:393-400; 2013. PMC3582709
95. Kim C, Pi-Sunyer X, Barrett-Connor E, Stentz FB, Murphy MB, Kong S, Nan B, Kitabchi AE, The Diabetes Prevention Program Research Group: Sex hormone binding globulin and sex steroids among premenopausal women in the Diabetes Prevention Program. *J Clin Endocrinol Metab* 98:3049-57; 2013. PMC3701280
 96. Golden SH, Kim C, Barrett-Connor E, Nan B, Kong S, Goldberg R, The Diabetes Prevention Program Research Group: The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the Diabetes Prevention Program. *Metabolism* 62:1313-1322; 2013. PMC3755098
 97. Pan Q, Delahanty LM, Jablonski KA, Knowler WC, Kahn SE, Florez JC, Franks PW, The Diabetes Prevention Program Research Group: Variation at the melanocortin 4 receptor gene and response to weight loss interventions in the Diabetes Prevention Program. *Obesity* 21:E520-E526; 2013.
 98. Goldberg R, Temprosa M, Otvos J, Brunzell J, Marcovina S, Mather K, Arakaki R, Watson K, Horton E, Barrett-Connor E, The Diabetes Prevention Program Research Group: Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. *J Clin Endocrinol Metab* 98:3989-3998; 2013. PMC3790618
 99. Davis NJ, Ma Y, Delahanty LM, Hoffman HJ, Mayer-Davis E, Franks PW, Brown-Friday J, Isonaga M, Kriska AM, Venditti EM, Wylie-Rosett J, The Diabetes Prevention Program Research Group: Predictors of sustained reduction in energy and fat intake in the Diabetes Prevention Program Outcomes Study intensive lifestyle intervention. *J Acad Nutr Diet* 113:1455-1464; 2013.
 100. Maruthur NM, Ma Y, Delahanty LM, Nelson JA, Aroda V, White NH, Marrero D, Brancati FL, Clark JM, The Diabetes Prevention Program Research Group: Early response to preventive strategies in the Diabetes Prevention Program. *J Gen Intern Med* 28:1629-1636; 2013. PMC3832727
 101. Marrero D, Pan Q, Barrett-Connor E, de Groot M, Zhang P, Percy C, Florez H, Ackermann R, Montez M, Rubin RR, The Diabetes Prevention Program Research Group: Impact of diagnosis of diabetes on health-related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. *Qual Life Res* 23:75-88; 2014. PMC3890371
 102. Kim C, Barrett-Connor E, Randolph JF, Kong S, Nan B, Mather KJ, Golden SH, The Diabetes Prevention Program Research Group: Sex steroid levels and response to weight loss interventions among postmenopausal women in the Diabetes Prevention Program. *Obesity* 22:882-887; 2014. PMC3818475
 103. Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, Kim C, Knowler WC, Christophi CA, Ratner R, The Diabetes Prevention Program Research Group: Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes. *Diabetes Care* 37:909-911; 2014. PMC3964494
 104. Florez H, Temprosa MG, Orchard TJ, Mather KJ, Marcovina SM, Barrett-Connor E, Horton E, Saudek C, Pi-Sunyer XF, Ratner RE, Goldberg RB, The Diabetes Prevention Program Research Group:

- Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. *Diabetes Obes Metab* 16:326-333; 2014. PMC3943638
105. Franks PW, Christophi CA, Jablonski KA, Billings LK, Delahanty LM, Horton ES, Knowler WC, Florez JC. The Diabetes Prevention Program Research Group: Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program. *Diabetologia* 57:485-490; 2014.
 106. Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, Mather KJ, Barrett-Connor E, Davis J, Florez JC, Wang TJ; The Diabetes Prevention Program Research Group: Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. *Diabetologia* 57:935-939; 2014.
 107. Mitri J, Nelson J, Ruthazer R, Garganta C, Nathan DM, Hu FB, Dawson-Hughes B, Pittas AG, The Diabetes Prevention Program Research Group: Plasma 25-hydroxyvitamin D and risk of metabolic syndrome: an ancillary analysis in the Diabetes Prevention Program. *Eur J Clin Nutr* 68:376-383; 2014. PMC4091839
 108. Billings LK, Jablonski KA, Ackerman RJ, Taylor A, Fanelli RR, McAteer JB, Guiducci C, Delahanty LM, Dabelea D, Kahn SE, Franks PW, Hanson RL, Maruthur NM, Shuldiner A, Mayer-Davis EJ, Knowler WC, Florez JC, The Diabetes Prevention Program Research Group: The influence of rare genetic variation in SLC30A8 on diabetes incidence and beta-cell function. *J Clin Endocrinol Metab* 99:E926-E930; 2014. PMC4010688
 109. Kim C, Golden SH, Kong S, Nan B, Mather KJ, Barrett-Connor E, The Diabetes Prevention Program Research Group: Does hormone therapy affect blood pressure changes in the Diabetes Prevention Program? *Menopause* 21:477-483; 2014. PMC3858523
 110. Venditti EM, Wylie-Rosett J, Delahanty LM, Mele L, Hoskin MA, Edelstein SL, The Diabetes Prevention Program Research Group: Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence. *Int J Behav Nutr Phys Act* 11:16; 2014. PMC4015875
 111. Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE, The Diabetes Prevention Program Research Group: Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the Diabetes Prevention Program except in those who develop diabetes. *Diabetes Care* 37:2253-2260; 2014. PMC4113172
 112. Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman, RF, The Diabetes Prevention Program Research Group: Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. *Diab Med* 31:1064-1068; 2014. PMC4138247
 113. Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF, Goldberg RB, The Diabetes Prevention Program Research Group: Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program Outcomes Study. *Diabetes Care*

37:2622-2631; 2014. PMC4140157

114. Delahanty LM, Pan Q, Jablonski KA, Aroda VR, Watson KE, Bray GA, Kahn SE, Florez JC, Perreault L, Franks PW, The Diabetes Prevention Program Research Group: Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. *Diabetes Care* 37:2738-2745; 2014. PMC4170126
115. Jaacks LM, Ma Y, Davis N, Delahanty LM, Mayer-Davis EJ, Franks PW, Brown-Friday J, Isonaga M, Kriska AM, Venditti EM, Wylie-Rosett J, The Diabetes Prevention Program Research Group: Long-term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. *Diabet Med* 31: 1631-1642; 2014. PMC4307949
116. Hoskin MA, Bray GA, Hattaway K, Khare-Ranade PA, Pomeroy J, Semler LN, Weinzierl VA, Wylie-Rosett J, The Diabetes Prevention Program Research Group: Prevention of diabetes through the lifestyle intervention: lessons learned from the Diabetes Prevention Program and Outcomes Study and its translation to practice. *Curr Nutr Rep* 3:362-378; 2014. PMC4221569
117. Hamman RF, Horton ES, Barrett-Connor E, Bray GA, Christophi CA, Crandall JP, Florez JC, Fowler S, Goldberg RB, Kahn SE, Knowler WC, Lachin JM, Murphy MB, Venditti EM, The Diabetes Prevention Program Research Group: Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcome Study. *Diabetes* 64:989-998; 2015. PMC4338587
118. The Diabetes Prevention Program Research Group*: HbA1c as a predictor of diabetes and as an outcome in the Diabetes Prevention Program: a randomized clinical trial. *Diabetes Care* 38:51-58; 2015. PMC4274777
119. Marrero DG, Ma Y, de Groot M, Horton ES, Price DW, Barrett-Connor E, Carnethon MR, Knowler WC, The Diabetes Prevention Program Research Group: Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. *Psychosom Med* 77:303-310; 2015. PMC4397126
120. Phelan S, Kanaya AM, Ma Y, Vittinghoff E, Barrett-Connor E, Wing R, Kusek JW, Orchard TJ, Crandall JP, Montez MG, Brown JS, The Diabetes Prevention Program Research Group: Long-term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. *Int J Urol* 22:206-212; 2015. PMC4387889
121. Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH, Barrett-Connor E, Delahanty LM, Montez MG, Ackermann RT, Zhuo X, Knowler WC, Ratner RE, The Diabetes Prevention Program Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program Outcomes Study 10-year follow-up. *J Clin Endocrinol Metab* 100:1646-1653; 2015. PMC4399293
122. Rockette-Wagner B, Edelstein S, Venditti EM, Reddy D, Bray GA, Carrion-Petersen ML, Dabelea D, Delahanty LM, Florez H, Franks PW, Montez MG, Rubin R, Kriska AM, The Diabetes Prevention Program Research Group: The impact of lifestyle intervention on sedentary time in individuals at high risk of diabetes. *Diabetologia* 58:1198-1202; 2015. PMC4417075
123. Mather KM, Kim C, Christophi CA, Aroda VR, Knowler WC, Edelstein SE, Florez JC, Labrie F, Kahn

- SE, Goldberg RB, Barrett-Connor E, The Diabetes Prevention Program Research Group. Steroid sex hormones, sex hormone binding globulin and diabetes incidence in the Diabetes Prevention Program. *J Clin Endocrinol Metab* 100:3778-3786; 2015.
124. Papandonatos GD, Pan Q, Pajewski NM, Delahanty LM, Peter I, Erar B, Ahmad S, Harden M, Chen L, Fontanillas P, GIANT Consortium, Wagenknecht LE, Kahn SE, Wing RR, Jablonski KA, Gordon S, Huggins¹⁴, Knowler WC, Florez JC, McCaffery JM, Franks PW, The Diabetes Prevention Program and The Look AHEAD Research Groups: Genetic predisposition to weight loss and regain with lifestyle intervention: analyses from the Diabetes Prevention Program and the Look AHEAD randomized controlled trials. *Diabetes* 64:4312-4321; 2015. PMC4657576
 125. The Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. *Lancet Diabetes Endocrinol* 3:866-875; 2015. PMC4623946
 126. Hivert MF, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, Horton ES, Pollin TI, Mather KJ, Perreault L, Barrett-Connor E, Knowler WC, Florez JC, The Diabetes Prevention Program Research Group: Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. *Diabetes* 65:520-526; 2016. PMC4747453
 127. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Tempresa MG, White NH, Crandall JP, The Diabetes Prevention Program Research Group: Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. *J Clin Endocrinol Metab* 101:1754-1761; 2016. PMC4880159
 128. Goldberg RB, Tempresa M, Mele L, Orchard TJ, Mather K, Bray GA, Horton E, Kitabchi A, Krakoff J, Marcovina SM, Perreault L, White N, The Diabetes Prevention Program Research Group: Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. *Metabolism* 65:764-775; 2016.
 129. Walford GA, Ma Y, Clish C, Florez JC, Wang TJ, Gerszten RE, Diabetes Prevention Program Research Group: Metabolite profiles of diabetes incidence and intervention response in the Diabetes Prevention Program. *Diabetes* 65:1424-1433; 2016. PMC4839205
 130. Hall KT, Jablonski KA, Chen L, Harden M, Tolkin BR, Kaptchuk TJ, Bray GA, Ridker PM, Florez JC; Diabetes Prevention Program Research Group, Mukamal KJ, Chasman DI: Catechol-O-methyltransferase association with hemoglobin A1c. *Metabolism* 65:961-967; 2016.
 131. Kim C, Barrett-Connor E, Aroda VR, Mather KJ, Christophi CA, Horton ES, Pi-Sunyer X, Bray GA, Labrie F, Golden SH, Diabetes Prevention Program Research Group: Testosterone and depressive symptoms among men in the Diabetes Prevention Program. *Psychoneuroendocrinology* 72:63-17; 2016.
 132. Ceglia L, Nelson J, Ware J, Alysandratos KD, Bray GA, Garganta C, Nathan DM, Hu FB, Dawson-Hughes B, Pittas AG, The Diabetes Prevention Program Research Group: Association between body weight and composition and plasma 25-hydroxyvitamin D level in the Diabetes Prevention Program.

Eur J Nutr 56:161-170; 2017.

133. McCaffery JM, Jablonski KA, Franks PW, Delahanty LM, Aroda V, Marrero D, Hamman RF, Horton ES, Dagogo-Jack S, Wylie-Rosett J, Barrett-Connor E, Kitabchi A, Knowler WC, Wing RR, Florez JC, Diabetes Prevention Program Research Group: Replication of the association of BDNF and MC4R variants with dietary intake in the Diabetes Prevention Program. *Psychosom Med* 79:224-233; 2017.
134. Rockette-Wagner B, Storti KL, Dabelea D, Edelstein S, Florez H, Franks PW, Montez MG, Pomeroy J, Kriska AM, Diabetes Prevention Program Research Group: Activity and sedentary time 10 years after a successful lifestyle intervention: The Diabetes Prevention Program. *Am J Prev Med* 52:292-299; 2017.
135. Goldberg RB, Aroda VR, Bluemke DA, Barrett-Connor E, Budoff M, Crandall JP, Dabelea D, Horton ES, Mather KJ, Orchard TJ, Schade D, Watson K, Temprosa M, Diabetes Prevention Program Research Group: Effect of long-term metformin and lifestyle in the diabetes prevention program and its outcome study on coronary artery calcium. *Circulation* 136:52-64; 2017.
136. Luchsinger JA, Ma Y, Christophi CA, Florez H, Golden SH, Hazuda H, Crandall J, Venditti E, Watson K, Jeffries S, Manly JJ, Pi-Sunyer FX, Diabetes Prevention Program Research Group: Metformin, lifestyle intervention, and cognition in the Diabetes Prevention Program Outcomes Study. *Diabetes Care* 40:958-965; 2017. PMC5481986
137. Billings LK, Jablonski KA, Warner AS, Cheng YC, McAteer JB, Tipton L, Shuldiner AR, Ehrmann DA, Manning AK, Dabelea D, Franks PW, Kahn SE, Pollin TI, Knowler WC, Altshuler D, Florez JC, Diabetes Prevention Program Research Group: Variation in maturity-onset diabetes of the young genes influence response to interventions for diabetes prevention. *J Clin Endocrinol Metab*, in press.

* Denotes member of the writing group

Genetics of NIDDM (GENNID) Study Publications

1. Raffen LJ, Robbins DC, Norris JM, Boerwinkle E, DeFronzo RA, Elbein SC, Fujimoto W, Hanis CL, Kahn SE, Permutt MA, Chiu KC, Cruz J, Ehrmann DA, Robertson RP, Rotter JI, Buse J: The GENNID Study: a resource for mapping the genes that cause NIDDM. *Diabetes Care* 19:864-872; 1996.
2. Ehm MG, Karnoub MC, Sakul H, Gottschalk K, Holt DC, Weber JL, Vaske D, Briley D, Briley L, Kopf J, McMillen P, Nguyen Q, Reisman M, Lai EH, Joslyn G, Shepherd NS, Bell C, Wagner MJ, Burns DK, American Diabetes Association GENNID Study Group: Genomewide search for type 2 diabetes susceptibility genes in four American populations. *Am J Hum Genet* 66:1871-1881; 2000.
3. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group: β -cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. *Diabetes* 51:2170-2178; 2002.
4. Duggirala R, Almasy L, Blangero J, Jenkinson CP, Arya R, DeFronzo RA, Stern MP, O'Connell P, American Diabetes Association GENNID Study Group: Further evidence for a type 2 diabetes susceptibility locus on chromosome 11q. *Genetic Epidemiology* 24:240-242; 2003.

5. Malhotra A, Wolford JK, American Diabetes Association GENNID Study Group: Analysis of quantitative lipid traits in the Genetics of NIDDM (GENNID) Study. *Diabetes* 54:3007-3014; 2005.
6. Malhotra A, Coon H, Feitosa MF, Li WD, North KE, Price RA, Bouchard C, Hunt SC, Wolford JK, American Diabetes Association GENNID Study Group: Meta-analysis of genome-wide linkage studies for quantitative lipid traits in African Americans. *Hum Mol Genet* 14:3955-3962; 2005.
7. Carr DB, Utzschneider KM, Hull RL, Tong J, Wallace TM, Kodama K, Shofer JB, Heckbert SR, Boyko EJ, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group: Gestational diabetes increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. *Diabetes Care* 29:2078-2083; 2006.
8. van Genugten RE, Utzschneider KM, Tong J, Gerchman F, Zraika S, Udayasankar J, Boyko EJ, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group: Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes. *Diabetes* 55:3529-3535; 2006.
9. Malhotra A, Elbein SC, Ng MCY, Duggirala R, Arya R, Imperatore G, Adeyemo A, Pollin TI, Hseuh W-C, Chan JCN, Rotimi C, Hanson RL, Hasstedt SJ, Wolford JK, American Diabetes Association GENNID Study Group: Meta-analysis of genome-wide linkage studies of quantitative lipid traits in families ascertained for type 2 diabetes. *Diabetes* 56:890-896; 2007.
10. Hasstedt SJ, Hanis CL, Elbein SC, American Diabetes Association GENNID Study Group: Univariate and bivariate linkage analysis identifies pleiotropic loci underlying lipid levels and type 2 diabetes risk. *Ann Hum Genet* 74:308-315; 2010.
11. Langberg KA, Ma L, Sharma NK, Hanis CL, Elbein SC, Hasstedt SJ, Das SK, American Diabetes Association GENNID Study Group: Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-American families from the GENNID study. *J Hum Genet* 57:57-61; 2012. PMC3266455
12. Faulenbach MV, Wright LA, Lorenzo C, Utzschneider KM, Goedecke JH, Fujimoto WY, Boyko EJ, McNeely MJ, Leonetti DL, Haffner SM, Kahn SE, American Diabetes Association GENNID Study Group: Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index. *J Diabetes Complications* 27:158-161; 2013. PMC3618472
13. Hasstedt SJ, Highland HM, Elbein SC, Hanis CL, Das SK, American Diabetes Association GENNID Study Group: Five linkage regions each harbor multiple type 2 diabetes genes in the African American subset of the GENNID Study. *J Hum Genet* 58:378-383; 2013. PMC3692593

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Publications

1. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM, The GRADE Study Research Group: Rationale and design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study. *Diabetes Care* 36:2254-2261; 2013. PMC3714493

2. Devchand R, Nicols C, Gallivan JM, Tiktin M, Krause-Steinrauf H, Larkin M, Tuncer DM, GRADE Study Research Group: Assessment of a National Diabetes Education Program diabetes management booklet: The GRADE experience. *J Am Assoc Nurse Pract*, in press.

Look Ahead Publications

1. The Look AHEAD Research Group*: Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. *Control Clin Trials* 24:610-628, 2003.
2. The Look AHEAD Research Group: The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. *Obesity* 14:737-752; 2006.
3. Espeland MA, Dotson K, Jaramillo SA, Kahn SE, Harrison B, Montez M, Foreyt JP, Montgomery B, Knowler WC, The Look AHEAD Research Group: Consent for genetics studies among clinical trial participants: findings from Action for Health in Diabetes (Look AHEAD). *Clin Trials* 3:443-456; 2006. PMC2475573
4. Rejeski WJ, Lang W, Neiberg RH, Van Dorsten B, Foster GD, Maciejewski ML, Rubin R, Williamson DF, The Look AHEAD Research Group: Correlates of health-related quality of life in overweight and obese adults with type 2 diabetes. *Obesity* 14:870-883; 2006.
5. The Look AHEAD Research Group: Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. *Diab Vasc Dis Res* 3:202-215; 2006.
6. The Look AHEAD Research Group: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. *Diabetes Care* 30:1374-1383; 2007.
7. Ribisl PM, Lang W, Jaramillo SA, Jakicic JM, Stewart KJ, Bahnson J, Bright R, Curtis JF, Crow RS, Soberman JE, The Look AHEAD Research Group: Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: The Look AHEAD clinical trial. *Diabetes Care* 30:2679-2684; 2007.
8. Wing RR, Jakicic J, Neiberg R, Lang W, Blair SN, Cooper L, Hill JO, Johnson KC, Lewis CE, The Look AHEAD Research Group: Fitness, fatness, and cardiovascular risk factors in type 2 diabetes: The Look AHEAD Study. *Med Sci Sports Exerc* 39:2107-2116; 2007.
9. Bertoni AG, Clark JM, Feeney P, Yanovski SZ, Bantle J, Montgomery B, Safford MM, Herman WH, Haffner S, The Look AHEAD Research Group: Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: The Look AHEAD Study. *J Diabetes Complications* 22:1-9; 2008.
10. Heshka S, Ruggiero A, Bray GA, Foreyt J, Kahn SE, Lewis CE, Saad M, Schwartz AV, The Look AHEAD Research Group: Altered body composition in type 2 diabetes mellitus. *Int J Obes*, 32:780-787; 2008. PMC2921819

11. Raynor HA, Jeffery RW, Ruggiero AM, Clark JM, Delahanty LM, The Look AHEAD Research Group: Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) Trial. *Diabetes Care* 31:1299-1304; 2008.
12. Espeland MA, Regensteiner JG, Jaramillo SA, Gregg E, Knowler WC, Wagenknecht LE, Bahnson J, Haffner S, Hill J, Hiatt WR, The Look AHEAD Research Group: Measurement characteristics of the ankle-brachial index: results from the Action for Health in Diabetes study. *Vasc Med* 13:225-233; 2008.
13. Gorin AA, Niemeier HM, Hogan P, Coday M, DiLillo VG, Gluck ME, Wadden TA, West DS, Williamson D, Yanovski SZ, The Look AHEAD Research Group: Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: results from the Look AHEAD trial. *Arch Gen Psychiatry* 65:1447-1455; 2008.
14. Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K, The Look AHEAD Research Group: Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. *Arch Intern Med* 169:163-171; 2009.
15. Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC, Foreyt JP, Hill JO, Trencle DL, Vitolins MZ, The Look AHEAD Research Group: One-year weight losses in the Look AHEAD Study: factors associated with success. *Obesity* 17:713-722; 2009.
16. Jakicic JM, Jaramillo SA, Balsubramanyam A, Bancroft B, Curtis JM, Mathews A, Pereira M, Regensteiner JG, Ribisl PM, The Look AHEAD Research Group: Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. *Int J Obes* 33:305-316; 2009.
17. Kramer H, Reboussin D, Bertoni AG, Marcovina S, Lipkin E, Greenway FL III, Brancati FL, The Look AHEAD Research Group: Obesity and albuminuria among adults with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) Study. *Diabetes Care* 32:851-853; 2009.
18. Vitolins MZ, Anderson AM, Delahanty L, Raynor H, Miller GD, Mobley C, Reeves R, Yamamoto M, Champagne C, Wing RR, Mayer-Davis E, The Look AHEAD Research Group: Action for Health in Diabetes (Look AHEAD) Trial: Baseline evaluation of selected nutrients and food group intake. *J Am Diet Assoc* 109:1367-1375; 2009. PMC2804253
19. Phelan S, Kanaya AM, Subak LL, Hogan PE, Espeland MA, Wing RR, Burgio KL, Dilillo V, Gorin AA, West DS, Brown JS, The Look AHEAD Research Group: Prevalence and risk factors for urinary incontinence in overweight and obese diabetic women: the Look AHEAD study. *Diabetes Care* 32:1391-1397; 2009.
20. Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA, The Look AHEAD and ACCORD Research Groups: Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. *Clin Trials* 6:416-429; 2009.
21. Espeland MA, Bray GA, Neiberg R, Rejeski WJ, Knowler WC, Lang W, Cheskin LJ, Williamson D, Lewis CB, Wing R, The Look AHEAD Research Group: Describing patterns of weight changes using

- principal components analysis: results from the Action for Health in Diabetes (Look AHEAD) Research Group. *Ann Epidemiol* 19:701-710; 2009.
22. Curtis JM, Horton ES, Bahnson J, Gregg EW, Jakicic JM, Regensteiner JG, Ribisl PM, Soberman JE, Stewart KJ, Espeland MA, The Look AHEAD Research Group: Prevalence and predictors of abnormal cardiovascular responses to exercise testing among individuals with type 2 diabetes: the Look AHEAD study. *Diabetes Care* 33:901-907; 2010. PMC2845049
 23. Redmon JB, Bertoni AG, Connelly S, Fenney PA, Glasser SP, Glick H, Greenway F, Hesson LA, Lawlor MS, Montez M, Montgomery B, The Look AHEAD Research Group: Effect of Look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. *Diabetes Care* 33:1153-1158; 2010. PMC2875414
 24. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, West DS, Wing RR, Knowler WC, The Look AHEAD Research Group: Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss. *Diabetologia* 53:1581-1589; 2010. PMC3099396
 25. The Look AHEAD Research Group: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four-year results of the Look AHEAD trial. *Arch Intern Med* 170:1566-1575; 2010. PMC3084497
 26. Jakicic JM, Gregg E, Knowler W, Kelley DE, Lang W, Miller GD, Pi-Sunyer FX, Regensteiner JG, Rejeski WJ, Ribisl P, Walkup MP, Wolf DL, The Look AHEAD Research Group: Activity patterns of obese adults with type 2 diabetes in the Look AHEAD Study. *Med Sci Sports Exerc* 42:1995-2005; 2010. PMC2945405
 27. Gary-Webb TL, Baptiste-Roberts K, Pham L, Wesche-Thobaben J, Patricio J, Pi-Sunyer FX, Brown AF, Jones L, Brancati FL, The Look AHEAD Research Group: Neighborhood and weight-related health behaviors in the Look AHEAD (Action for Health in Diabetes) study. *BMC Public Health* 10:312; 2010. PMC2897795
 28. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM, Fatty Liver Subgroup of The Look AHEAD Research Group: Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. *Diabetes Care* 33:2156-2163; 2010. PMC2945152
 29. Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, Schwenke DC, Tracy RP, Pi-Sunyer FX, Ballantyne CM, The Look AHEAD Research Group: A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) Study. *Diabetes Care* 33:2297-2303; 2010. PMC2963483
 30. Foy CG, Lewis CE, Hairston KG, Miller GD, Lang W, Jakicic JM, Rejeski WJ, Ribisl PM, Walkup MP, Wagenknecht LE, The Look AHEAD Research Group: Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD Trial. *Obesity* 19:83-93; 2011. PMC3408003

31. Gary-Webb TL, Baptiste-Roberts K, Pham L, Wesche-Thobaben, Patricio J, Pi-Sunyer FX, Brown AF, Jones-Corneille L, Brancati FL, The Look AHEAD Research Group: Neighborhood socioeconomic status, depression, and health status in the Look AHEAD (Action for Health in Diabetes) study. *BMC Public Health* 11:349; 2011. PMC3111582
32. Belalcazar LM, Ballantyne CM, Lang W, Haffner SM, Rushing J, Schwenke DC, Pi-Sunyer FX, Tracy RP, The Look AHEAD Research Group: Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the Look AHEAD Study. *Arterioscler Thromb Vasc Biol* 31:1689-1695; 2011. PMC3130500
33. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L, The Look AHEAD Research Group: Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care* 31:1481-1486; 2011. PMC3120182
34. The Look AHEAD Research Group: The development and description of the comparison group in the Look AHEAD trial. *Clin Trials* 8:320-329; 2011. PMC3198118
35. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wing RR, The Look AHEAD Research Group: Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. *Diabetes Care* 34:2152-2157; 2011. PMC3177753
36. Wadden TA, Neiberg RH, Wing RR, Clark JM, Delahanty LM, Hill JO, Krakoff J, Otto A, Ryan DH, Vitolins MZ, The Look AHEAD Research Group: Four-year weight losses in the Look AHEAD study: factors associated with long-term success. *Obesity* 19:1987-1998; 2011. PMC3183129
37. Smart-Halajko MC, Kelley-Hedgepeth A, Montefusco MC, Cooper JA, Kopin A, McCaffrey JM, Balasubramanyam A, Pownall HJ, Nathan DM, Peter I, Talmud PJ, Huggins GS, The Look AHEAD Research Group: ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. *BMC Med Genet* 12:89; 2011. PMC3146919
38. Mount DL, Davis C, Kennedy B, Raatz S, Dotson K, Gary-Webb TL, Thomas S, Johnson KC, Espeland MA, The Look AHEAD Research Group: Factors influencing enrollment of African Americans in the Look AHEAD trial. *Clin Trials* 9:80-89; 2012. PMC3843916
39. Brancati FL, Evans M, Furberg CD, Gellner N, Kahn SE, Kaufmann PG, Lewis CE, Nathan DM, Pitt B, Safford MM, The Look AHEAD Research Group: Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. *Clin Trials* 9:113-124; 2012. PMC3790961
40. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, Cooper-DeHoff RM, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q, Gieger C, Gilhuijs-Pederson LA, Glessner JT, Goel A, Gong Y, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger

- C, Kumari M, Langae TY, Lawlor DA, Li M, Lobmeyer MT, Maitland-van der Zee AH, Meijs MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Wolffenbuttel BH, Young T, Zafarmand MH, Zmuda JM; Look AHEAD Research Group; DIAGRAM consortium, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Sever P, Poulter N, Caulfield M, Dominiczak A, Shields DC, Bhatt DL, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevendans PA, Dorn GW 2nd, Farrall M, FitzGerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, Johnson JA, Klungel OH, Knowler WC, Koenig W, März W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs FW, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJ: Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. *Am J Hum Genet* 90:410-425; 2012. PMC3309185
41. Schwartz AV, Johnson KC, Kahn SE, Shepherd JA, Nevitt MC, Peters AL, Walkup MP, Hodges A, Williams CC, Bray GA, The Look AHEAD Research Group: Effect of one year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the Look AHEAD randomized trial. *J Bone Miner Res* 27:619-627; 2012. PMC3410035
 42. Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, Zhang Q, The Look AHEAD Research Group: Lifestyle change and mobility in obese adults with type 2 diabetes. *N Engl J Med* 366:1209-1217; 2012. PMC3339039
 43. Faulconbridge LF, Wadden TA, Rubin RR, Wing RR, Walkup MP, Fabricatore AN, Coday M, Van Dorsten B, Mount DL, Ewing LJ, The Look AHEAD Research Group: One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. *Obesity* 20:783-793; 2012. PMC3298842
 44. Phelan S, Kanaya AM, Subak LL, Hogan PE, Espeland MA, Wing RR, Burgio KL, DiLillo V, Gorin AA, West DS, Brown JS, The Look AHEAD Research Group: Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD Trial. *J Urol* 187:939-944; 2012. PMC3646565
 45. McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty LM, Cheskin LJ, Balasubramanyam A, Wagenknecht LE, Wing RR, Genetic Subgroup of Look AHEAD, The Look AHEAD Research Group: Obesity susceptibility loci and dietary intake in the Look AHEAD Trial. *Am J Clin Nutr* 95:1477-1486; 2012. PMC3349457
 46. Neiberg RH, Wing RR, Bray GA, Reboussin DM, Rickman AD, Johnson KC, Kitabchi AE, Faulconbridge LF, Kitzman DW, Espeland MA, The Look AHEAD Research Group: Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study. *Obesity* 20:2048-2056; 2012. PMC3632374
 47. Belalcazar LM, Lang W, Haffner SM, Hoogeveen RC, Pi-Sunyer FX, Schwenke DC, Balasubramanyam A, Tracy RP, Kriska AP, Ballantyne CM, The Look AHEAD Research Group:

- Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. *J Lipid Res* 53:2726-2733; 2012. PMC3494242
48. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ, Johnson KC, Safford MM, Kitabchi AE, Pi-Sunyer FX, Wing RR, Bertoni AG, The Look AHEAD Research Group: Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA* 308:2489-2496; 2012.
 49. Ribisl PM, Gaussoin SA, Lang W, Bahnson J, Connelly SA, Horton ES, Jakicic JM, Killean T, Kitzman DW, Knowler WC, Stewart KJ, The Look AHEAD Research Group: Lifestyle intervention improves heart rate recovery from exercise in adults with type 2 diabetes: results from the Look AHEAD study. *J Obes* 2012:309196; 2012. PMC3512322
 50. Peter I, McCaffery JM, Kelley-Hedgpeath A, Hakonarson H, Reis S, Wagenknecht LE, Kopin AS, Huggins GS, Genetics Subgroup of the Look AHEAD Study, The Look AHEAD Research Group: Association of type 2 diabetes susceptibility loci with one-year weight loss in the Look AHEAD clinical trial. *Obesity* 20:1675-1682; 2012. PMC3406235
 51. Miller GD, Jakicic JM, Rejeski WJ, Whit-Glover MC, Lang W, Walkup MP, Hodges M, The Look AHEAD Research Group: Effect of varying accelerometry criteria on physical activity: the Look AHEAD Study. *Obesity* 21:32-44; 2013. PMC3430806
 52. Unick JL, Beavers D, Bond DS, Clark JM, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wagenknecht LE, Wing RR, The Look AHEAD Research Group: The long-term effectiveness of a lifestyle intervention in severely obese individuals. *Am J Med* 126:236-242; 2013. PMC3574274
 53. Rubin RR, Peyrot M, Gaussoin SA, Espeland MA, Williamson D, Faulconbridge LF, Wadden TA, Ewing L, Safford M, Evans-Hudnall G, Wing RR, Knowler WC, The Look AHEAD Research Group: Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. *Diabetes Care* 36:1088-1094; 2013. PMC3631821
 54. Jakicic JM, Egan CM, Fabricatore AN, Gaussoin SA, Glasser SP, Hesson LA, Knowler WC, Lang W, Regensteiner JG, Ribisl PM, Ryan DH, The Look AHEAD Research Group: Four-year change in cardiorespiratory fitness and influence on glycemic control in adults with type 2 diabetes in a randomized trial: The Look AHEAD Trial. *Diabetes Care* 36:1297-1303; 2013. PMC3631819
 55. The Look AHEAD Research Group*: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 369:145-154; 2013. PMC3791615
 56. McCaffery JM, Papandonatos GD, Huggins GS, Peter I, Erar B, Kahn SE, Knowler WC, Lipkin EW, Kitabchi AE, Wagenknecht LE, Wing RR, Genetic Subgroup of Look AHEAD, The Look AHEAD Research Group: Human cardiovascular disease IBC chip-wide association with weight loss and weight regain in the Look AHEAD trial. *Hum Hered* 75:160-174; 2013. PMC4257841
 57. McCaffery JM, Papandonatos GD, Huggins GS, Peter I, Kahn SE, Knowler WC, Hudnall GE, Lipkin E, Kitabchi AE, Wagenknecht LE, Wing RR, Genetic Subgroup of Look AHEAD, The Look AHEAD

- Research Group: *FTO* predicts weight regain in the Look AHEAD Clinical Trial. *Int J Obes* 36:1545-1552; 2013. PMC3750057
58. Huggins GS, Papandonatos GD, Erar B, Belalcazar LM, Brautbar A, Ballantyne C, Kitabchi AE, Wagenknecht LE, Knowler WC, Pownall HJ, Wing RR, Peter I, McCaffery JM, Genetics Subgroup of the Action for Health in Diabetes (Look AHEAD) Study: Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus? The Action for Health in Diabetes (Look AHEAD) study. *Circ Cardiovasc Genet* 6:391-399; 2013.
 59. Wing RR, Reboussin D, Lewis CE, The Look AHEAD Research Group: Intensive lifestyle intervention in type 2 diabetes (letter). *N Eng J Med* 369:2358-2359; 2013. PMC3791615
 60. The Look AHEAD Research Group: Eight-year weight losses with an intensive lifestyle intervention: The Look AHEAD Study. *Obesity* 22:5-13; 2014. PMC3904491
 61. Fitzpatrick SL, Jeffery R, Johnson KC, Roche CC, Van Dorsten B, Gee M, Johnson RA, Charleston J, Dotson K, Walkup MP, Hill-Briggs F, Brancati FL, The Look AHEAD Research Group. Baseline predictors of missed visits in the Look AHEAD study. *Obesity* 22:131-140; 2014. PMC3943994
 62. Espeland MA, Lewis CE, Bahnson J, Knowler WC, Regensteiner JG, Gaussoin SA, Beavers D, Johnson KC, The Look AHEAD Research Group: Impact of weight loss on ankle-brachial index and inter-artery blood pressures in overweight and obese adults with diabetes. *Obesity* 22:1032-1041; 2014. PMC3968218
 63. Peter I, Papandonatos GD, Belalcazar LM, Yang Y, Erar B, Jakicic JM, Unick JL, Balasubramanyam A, Lipkin EW, Delahanty LM, Wagenknecht LE, Wing RR, McCaffery JM, Huggins GS, The Look AHEAD Research Group: Genetic modifiers of cardiorespiratory fitness response to lifestyle intervention. *Med Sci Sports Exerc* 46:302-311; 2014. PMC4055466
 64. Wing RR, Leahey T, Jeffery R, Johnson KC, Hill JO, Coday M, Espeland MA, The Look AHEAD Research Group: Do weight loss and adherence cluster within behavioral treatment groups? *Obesity* 22:638-644; 2014. PMC3859866
 65. Breyer BN, Phelan S, Hogan PE, Rosen RC, Kitabchi AE, Wing RR, Brown JS, The Look Ahead Research Group: Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: Results from the Look AHEAD Trial. *J Urol* 192:144-149; 2014.
 66. Gibbs BB, Brancati FL, Chen H, Coday M, Jakicic JM, Lewis CE, Stewart KL, Clark JM, The Look AHEAD Research Group: Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. *Eur J Prev Cardiol* 21:608-617; 2014. PMC3812302
 67. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshes A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, Cooper-Dehoff RM, Gaunt TR, Gieger C, Gong Y, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, Monda KL, Onland-Moret NC, Nelson CP, O'Connell JR, Ordovas J, Peter I, Peters A, Shaffer J, Shen H, Smith E, Speilotes L, Thomas F, Thorand B, Monique Verschuren WM, Anand SS, Dominiczak A,

- Davidson KW, Hegele RA, Heid I, Hofker MH, Huggins GS, Illig T, Johnson JA, Kirkland S; Look AHEAD Research Group, König W, Langae TY, McCaffery J, Melander O, Mitchell BD, Munroe P, Murray SS, Papanicolaou G, Redline S, Reilly M, Samani NJ, Schork NJ, Van Der Schouw YT, Shimbo D, Shuldiner AR, Tobin MD, Wijmenga C, Yusuf S; GIANT Consortium; CARE IBC Consortium, Hakonarson H, Lange LA, Demerath EW, Fox CS, North KE, Reiner AP, Keating B, Taylor KC: Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. *Hum Mol Genet* 23:2498-2510; 2014. PMC3988452
68. The Look AHEAD Research Group: Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: The Look AHEAD Trial. *Diabetes Care* 37:1544-1553; 2014. PMC4030096
 69. Unick JL, Hogan PE, Neiberg RH, Cheskin LJ, Dutton GR, Evans-Hudnall G, Jeffery R, Kitabchi AE, Nelson JA, Pi-Sunyer FX, West DS, Wing RR, The Look AHEAD Research Group: Evaluation of early weight loss thresholds for identifying nonresponders to an intensive lifestyle intervention. *Obesity* 22:1608-1616; 2014. PMC4077939
 70. Espeland MA, Glick HA, Bertoni A, Brancati FL, Bray GA, Clark JM, Curtis JM, Egan C, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Hazuda HP, Hill JO, Hire D, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Killean T, Kitabchi AE, Knowler WC, Kriska A, Lewis CE, Miller M, Montez MG, Murillo A, Nathan DM, Nyenwe E, Patricio J, Peters AL, Pi-Sunyer X, Pownall H, Redmon JB, Rushing J, Ryan DH, Safford M, Tsai AG, Wadden TA, Wing RR, Yanovski SZ, Zhang P, The Look AHEAD Research Group: Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the Action for Health in Diabetes. *Diabetes Care* 37:2548-2556; 2014. PMC4140155
 71. Lipkin EW, Schwartz AV, Anderson AM, Davis C, Johnson KC, Gregg EW, Bray GA, Berkowitz R, Peters AL, Hodges A, Lewis C, Kahn SE, The Look AHEAD Research Group: The Look AHEAD Trial: bone loss at 4-year follow-up in type 2 diabetes. *Diabetes Care* 37:2822-2829; 2014. PMC4170123
 72. Espeland MA, Rapp SR, Bray GA, Houston DK, Johnson KC, Kitabchi AE, Hergenroeder AL, Williamson J, Jakicic JM, van Dorsten B, Kritchevsky SB; Action for Health In Diabetes (Look AHEAD) Movement and Memory Subgroup, The Look AHEAD Research Group: Long-term impact of behavioral weight loss intervention on cognitive function. *J Gerontol A Biol Sci Med Sci* 69:1101-1108; 2014. PMC4158413
 73. The Look AHEAD Research Group*: Effect of a long-term behavioral weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD randomized clinical trial. *Lancet Diabetes Endocrinol* 2:801-809; 2014. PMC4443484
 74. Wing RR, The Look AHEAD Research Group: Implications of Look AHEAD for clinical trials and clinical practice. *Diabetes Obes Metab* 16:1183-1191; 2014. PMC4227940
 75. Knowler WC, Bahnson JL, Bantle JP, Lewis CE, The Look AHEAD Research Group: Diabetic kidneys do deserve a lifestyle change. *Lancet Diabetes Endocrinol* 2:776; 2014. (letter)

76. Pownall HJ, Bray GA, Wagenknecht LE, Walkup MP, Heshka S, Hubbard VS, Hill J, Kahn SE, Nathan DM, Schwartz AV, Johnson KC, The Look AHEAD Research Group: Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: The Look AHEAD Study. *Obesity* 23:565-572; 2015.
77. Raynor HA, Anderson AM, Miller GD, Reeves R, Delahanty LM, Vitolins MZ, Harper P, Mobley C, Konersman K, Mayer-Davis E, The Look AHEAD Research Group: Partial meal replacement plan and quality of the diet at 1 year: Action for Health in Diabetes (Look AHEAD) Trial. *J Acad Nutr Diet* 115:731-742; 2015. PMC4410067
78. Rejeski WJ, Bray GA, Chen SH, Clark JM, Evans M, Hill JO, Jakicic JM, Johnson KC, Neiberg R, Ip EH, The Look AHEAD Research Group: Aging and physical function in type 2 diabetes: 8 years of an intensive lifestyle intervention. *J Gerontol A Biol Sci Med Sci* 70:345-353; 2015.
79. Belalcazar LM, Anderson AM, Lang W, Schwenke DC, Haffner SM, Yatsuya H, Rushing J, Vitolins MZ, Reeves R, Pi-Sunyer FX, Tracy RP, Ballantyne CM, The Look AHEAD Research Group: Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1. *J Acad Nutr Diet* 114:1800-1810; 2014. PMC4253047
80. The Look AHEAD Research Group*: Prospective association of a genetic risk score and lifestyle intervention with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD randomised controlled trial. *Diabetologia* 58:1803-1813; 2015. PMC4507276
81. Unick JL, Neiberg RH, Hogan PE, Cheskin LJ, Dutton GR, Jeffery R, Nelson JA, Pi-Sunyer X, West DS, Wing RR, The Look AHEAD Research Group: Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later. *Obesity* 23:1353-1356; 2015. PMC4481874
82. Belalcazar LM, Papandonatos GD, McCaffery JM, Peter I, Pajewski NM, Erar B, Allred ND, Balasubramanyam A, Bowden DW, Brautbar A, Pi-Sunyer FX, Ballantyne CM, Huggins GS, The Look AHEAD Research Group: A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. *Physiol Genomics* 47:215-224; 2015. PMC4451387
83. Alonso A, Bahnson JL, Gaussoin SA, Bertoni AG, Johnson KC, Lewis CE, Vetter M, Mantzoros CS, Jeffery RW, Soliman EZ, The Look AHEAD Research Group: Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: The Look AHEAD randomized trial. *Am Heart J* 170:770-777; 2015. PMC4576158
84. Belalcazar LM, Lang W, Haffner SM, Schwenke DC, Kriska A, Balasubramanyam A, Hoogeveen RC, Pi-Sunyer FX, Tracy RP, Ballantyne CM, The Look AHEAD (Action for Health in Diabetes) Research Group: Improving adiponectin levels in individuals with diabetes and obesity: insights from Look AHEAD. *Diabetes Care* 38:1544-1550; 2015. PMC4512135
85. McCaffery JM, Papandonatos GD, Faulconbridge LF, Erar B, Peter I, Wagenknecht LE, Pajewski NM, Anderson A, Wadden TA, Wing RR, The Look AHEAD Research Group: Genetic predictors of depressive symptoms in the Look AHEAD Trial. *Psychosom Med* 77:982-992; 2015. PMC4643359

86. Unick JL, Gaussoin S, Bahnson J, Crow R, Curtis J, Killean T, Regensteiner JG, Stewart KJ, Wing RR, Jakicic JM, The Look AHEAD Research Group: Validity of ratings of perceived exertion in patients with type 2 diabetes. *J Nov Physiother Phys Rehabil* 1:102; 2014. PMC4255703
87. The Look AHEAD Research Group: Prospective association of GLUL rs10911021 with cardiovascular morbidity and mortality among individuals with type 2 diabetes: The Look AHEAD Study. *Diabetes* 65:297-302; 2016. PMC4686954
88. White DK, Neogi T, Rejeski WJ, Walkup MP, Lewis CE, Nevitt MC, Foy CG, Felson DT; Look AHEAD Research Group: Can an intensive diet and exercise program prevent knee pain among overweight adults at high risk? *Arthritis Care Res* 67:965-971; 2015. PMC4482772
89. Belalcazar LM, Papandonatos GD, Erar B, Peter I, Alkofide H, Balasubramanyam A, Brautbar A, Kahn SE, Knowler WC, Ballantyne CM, McCaffery JM, Huggins GS, Genetics Subgroup of the Look AHEAD Study: Lifestyle intervention for weight loss and cardiometabolic changes in the setting of glucokinase regulatory protein inhibition: glucokinase regulatory protein-Leu446Pro variant in Look AHEAD. *Circ Cardiovasc Genet* 9:71-78; 2016. PMC4758870
90. Marquez B, Anderson A, Wing RR, West DS, Newton RL, Meacham M, Hazuda HP, Peters A, Montez MG, Broyles ST, Walker M, Evans-Hudsnall G; The Look AHEAD Research Group: The relationship of social support with treatment adherence and weight loss in Latinos with type 2 diabetes. *Obesity* 24:568-575; 2016. PMC4769665
91. The Look AHEAD Research Group*: Severe hypoglycemia in the Look AHEAD trial. *J Diabetes Complications* 30:935-943; 2016. PMC4912885
92. Belalcazar LM, Haffner SM, Lang W, Hoogeveen RC, Rushing J, Schwenke DC, Tracy RP, Pi-Sunyer FX, Kriska AM, Ballantyne CM, The Look AHEAD Research Group: Lifestyle intervention and/or statins for the reduction of C-reactive protein in diabetes: from the Look AHEAD Study. *Obesity* 21:944-950; 2013. PMC3689862
93. Espeland MA, Rejeski WJ, West DS, Bray GA, Clark JM, Peters AL, Chen H, Johnson KC, Horton ES, Hazuda HP: Intensive weight loss intervention in older individuals: results from the Action for Health in Diabetes Type 2 Diabetes Mellitus trial. *J Am Geriatr Soc* 62:912-922; 2013. PMC4123658
94. Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC, The Look AHEAD Research Group, The ACCORD Study Group: Systolic blood pressure control among individuals with type 2 diabetes: a comparative effectiveness analysis of three interventions. *Am J Hypertens* 28:995-1009; 2015. PMC4506323
95. Neiberg RH, Rejeski JR, Applegate WB, Clark JM, Knowler WC, Bray GA, Espeland MA, Cheskin LJ, The Look AHEAD Research Group: Self-reported gastrointestinal symptoms in type 2 diabetes improve with an intensive lifestyle intervention: results from the Action for Health in Diabetes (Look AHEAD) Clinical Trial. *Clin Diabetes* 33:181-188; 2015. PMC4608270

96. Zhang P, Hire D, Espeland MA, Knowler WC, Thomas S, Tsai AG, Glick HA, The Look AHEAD Research Group: Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: Results from the Look AHEAD trial. *Obesity* 24:856-864; 2016. PMC4817364
97. The Look AHEAD Research Group: Association of weight loss maintenance and weight regain on 4-year changes in CVD risk factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. *Diabetes Care* 39:1345-1355; 2016. PMC4955927
98. Unick JL, Gaussoin SA, Hill JO, Jakicic JM, Bond DS, Hellgren M, Johnson KC, Peters AL, Coday M, Kitzman DW, Bossart S, Wing RR, The Look AHEAD Research Group: Four-year physical activity levels among intervention participants with type 2 diabetes. *Med Sci Sports Exerc* 48:2437-2445; 2016. PMC5110392
99. Pownall HJ, Schwartz AV, Bray GA, Berkowitz RI, Lewis CE, Boyko EJ, Jakicic JM, Chen H, Heshka S, Gregg EW, Johnson KC, The Look AHEAD Research Group: Changes in regional body composition over 8 years in a randomized trial: The Look AHEAD Study. *Obesity* 24:1899-1905; 2017. PMC5134917
100. Rapp SR, Luchsinger JA, Baker LD, Blackburn GL, Hazuda HP, Demos-McDermott KE, Jeffery RW, Keller JN, McCaffery JM, Pajewski NM, Evans M, Wadden TA, Arnold SE, Espeland MA, The Look AHEAD Research Group: Effect of a long-term intensive lifestyle intervention on cognitive function: Action for Health in Diabetes Study. *J Am Geriatr Soc* 65:966-972; 2017. PMC5435531
101. Espeland MA, Luchsinger JA, Baker LD, Neiberg R, Kahn SE, Arnold SE, Wing RR, Blackburn GL, Bray G, Evans M, Hazuda HP, Jeffery RW, Wilson VM, Clark JM, Coday M, Demos-McDermott K, Foreyt JP, Greenway F, Hill JO, Horton ES, Jakicic JM, Johnson KC, Knowler WC, Lewis CE, Nathan DM, Peters A, Pi-Sunyer X, Pownall H, Wadden TA, Rapp SR, The Look AHEAD Research Group: Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. *Neurology* 88:2026-2035; 2017. PMC5440245
102. The Look AHEAD Research Group: Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. *Diabetologia* 60:980-988; 2017. PMC5423967
103. Rushing J, Wing R, Wadden TA, Knowler WC, Lawlor M, Evans M, Killean T, Montez M, Espeland MA, Zhang P, The Look AHEAD Research Group: Cost of intervention delivery in a lifestyle weight loss trial in type 2 diabetes: results from the Look AHEAD clinical trial. *Obes Sci Pract* 3:15-24; 2017. PMC5358076
104. Espeland MA, Luchsinger JA, Baker LD, Neiberg R, Kahn SE, Arnold SE, Wing RR, Blackburn GL, Bray G, Evans M, Hazuda HP, Jeffery RW, Wilson VM, Clark JM, Coday M, Demos-McDermott K, Foreyt JP, Greenway F, Hill JO, Horton ES, Jakicic JM, Johnson KC, Knowler WC, Lewis CE, Nathan DM, Peters A, Pi-Sunyer X, Pownall H, Wadden TA, Rapp SR, Look AHEAD Study Group: Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. *Neurology* 88:2026-2035; 2017. PMC5440245
105. Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP, Garcia KR, Glasser S, Greenway FL, Gregg EW, Hazuda HP, Hergenroeder A, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Kahn SE,

Knowler WC, Lewis CE, Miller M, Montez MG, Nathan DM, Patricio JL, Peters AL, Pi-Sunyer X, Pownall HJ, Reboussin D, Redmon JB, Steinberg H, Wadden TA, Wagenknecht LE, Wing RR, Womack CR, Yanovski SZ, Zhang P, Schwartz AV: The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD Randomized Clinical Trial. *J Bone Miner Res*, in press.

* Denotes member of the writing group

Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Publications

1. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR, The NAVIGATOR Study Group: Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. *Am Heart J* 156:623-632; 2008.
2. Bethel MA, Deedwania P, Levitt NS, Schmitz O, Huntsman-Labed A, Califf RM, Haffner SM, Diem P, The NAVIGATOR Study Group: Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. *Diabet Med* 26:1204-1211; 2009.
3. The NAVIGATOR Study Group*: Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med* 362:1463-1476; 2010.
4. The NAVIGATOR Study Group: Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med* 362:1477-1490; 2010.
5. Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, Haffner SM, Bethel MA, Holman RR, Califf RM: Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. *Cardiovasc Ther* 28:124-132; 2010.
6. Bethel MA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Kahn SE, Levitt NS, McMurray JJV, Raptis SA, Thomas L, Sun JL, Haffner SM: A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. *Am J Cardiol* 112:231-237; 2013.
7. Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ: Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. *Am Heart J* 166:935-940; 2013.
8. Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H: Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. *BMJ* 347:f6745; 2013 (DOI:10.1136/bmj.f6745).

9. Yates T, Haffner SM, Schulte PJ, Thomas L, Huffman KM, Bales CW, Califf RM, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Davies MJ, Kraus WE: Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. *Lancet* 383:1059-1066; 2014.
10. Huffman KM, Sun JL, Thomas L, Bales CW, Califf RM, Yates T, Davies MJ, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Haffner SM, Kraus WE: Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. *Metabolism* 63:554-561; 2014.
11. Preiss D, Haffner SM, Thomas LE, Sun JL, Sattar N, Yates T, J Davies M, McMurray JJ, Holman RR, Califf RM, Kraus WE: Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. *Diabetes Obes Metab* 16:1265-1268; 2014.
12. Preiss D, Thomas LE, Wojdyla DM, Haffner SM, Gill JM, Yates T, Davies MJ, Holman RR, McMurray JJ, Califf RM, Kraus WE, NAVIGATOR Investigators: Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. *BMJ Open* 5:e007901; 2015.

* Denotes member of the writing group

Restoring Insulin Secretion (RISE) Publications

1. The RISE Consortium*: Restoring Insulin Secretion (RISE): Design of studies of β -cell preservation in prediabetes and early type 2 diabetes across the lifespan. *Diabetes Care* 37:780-788; 2014. PMC3931376
2. Hannon TS, Kahn SE, Utschneider KM, Buchanan TA, Nadeau KJ, Zeitler P, Ehrmann DA, Arslanian SA, Caprio S, Edelstein SL, Savage PJ, Mather KJ, The RISE Consortium: Review of methods for measuring β -cell function: design considerations from the Restoring Insulin Secretion (RISE) Consortium. *Diabetes Obes Metab*, in press.

* Denotes member of the writing group

Manuscripts on which Authorship Was Voluntarily Withdrawn Because of Disagreement with the Publishing Principles of Reed Elsevier (Name Listed in Acknowledgements)

1. Rojas JM, Matsen ME, Munding TO, Morton GJ, Stefanovski D, Bergman RN, Kaiyala KJ, Taborsky GJ, Schwartz MW: Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response. *Mol Metab* 4:561-568; 2015. PMC4529498
2. Barry DR, Utschneider KM, Tong J, Gaba K, Leotta DF, Brunzell JD, Easterling TR: Intraabdominal fat, insulin sensitivity, and cardiovascular risk factors in postpartum women with a history of preeclampsia. *Am J Obstet Gynecol* 213:104.e1-e11; 2015.
3. Ikizler HO, Zelnick L, Ruzinski J, Curtin L, Utschneider K, Kahn S, Kestenbaum B, Himmelfarb J, Iannaccone I, de Boer I: Dietary acid load is associated with serum bicarbonate but not insulin sensitivity in chronic kidney disease. *J Renal Nutr* 26:93-102; 2016. PMC4762747

4. The Look AHEAD Research Group: Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol* 4:913-921; 2016. PMC5094846
5. Kocarnik BM, Boyko EJ, Matsumoto AM, Fujimoto WY, Hayashi T, Leonetti DL, Page ST: Baseline estradiol concentration in community-dwelling Japanese American men is not associated with intra-abdominal fat accumulation over 10 years. *Obes Res Clin Pract* 10:624-632; 2016. PMC4930416
6. Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR, Levin A, Thomas MC, Wanner C, Ksiske BL, Wheeler DC, Groop PH: Management of patients with diabetes and CKD: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney Int* 90:1175-1183; 2016.
7. Goedecke JH, George C, Veras K, Peer N, Lombard C, Victor H, Steyn K, Levitt NS: Sex differences in insulin sensitivity and insulin response with increasing age in black South African men and women with normal glucose tolerance. *Diabetes Res Clin Pract* 122:207-214; 2016.